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Pregnancy is dependent on the development of maternal immune tolerance to the genetically foreign 
fetus. During pregnancy the mother’s immune reactivity and energy metabolism undergoes significant 
changes and the levels of certain hormones in peripheral blood are significantly increased. Hormones 
are important regulators of the functional activity of the immune system and immune cells within. 
Hormones secreted by the placenta, protect the fetus from the maternal immune response of the 
mother, emphasizing their immunomodulatory effects. Therefore, hormonal regulation is essential for 
the functional activity of immune cells.  
 
There is evidence that the hormone, kisspeptin, plays a role in the development of immune tolerance 
during pregnancy based on its role in the regulation of the adaptive T regulatory (aTreg)/T-helper 17 
(Th17) cells, induction of the enzyme indoleamine 2,3-dioxygenase (IDO) and regulation of monocyte 
function during pregnancy. In addition, kisspeptin has been implicated in the regulation of specific 
cytokines during pregnancy. It is crucial to maintain an appropriate cytokine balance at the maternal–
fetal interface as well as in circulation. Several pregnancy-related disorders have been associated with 
a variation in Th1/Th2/Th17 cytokines and aTreg cell subsets. Kisspeptin has been implicated in 
regulating cytokines IL-10 and IL-17A as well as aTreg and Th17 cells which are significant role players 
in immune tolerance during pregnancy. However, its effect on other pro- and anti-inflammatory 
cytokines remain unknown. Therefore, more research is required to better understand the role of 
kisspeptin in the development of immune tolerance during pregnancy. The hypothesis of this study is 
that kisspeptin alters the expression of anti-and pro-inflammatory cytokines and may thus influence 
the establishment of immune tolerance in pregnancy. To test this hypothesis, we used a previously 
established in vitro peripheral blood mononuclear cell (PBMC) Mycobacterium tuberculosis (Mtb) 
infection assay model as well as a newly established in vitro infection model using lipopolysaccharide 
(LPS)-stimulated whole blood. 
 
Protein expression analysis of selected pro- and anti-inflammatory cytokines was performed on PBMC 
infected with Mtb and on whole blood cells stimulated with LPS in the absence and presence of 
kisspeptin-10 for different times. The cytokines levels were measured by luminex multiplex assay and 
sandwich ELISA, respectively. Results from the PBMC infection assay showed a varied but not 
statistically significant effect of kisspeptin-10 on selected pro- and anti-inflammatory cytokine 
expression at 2 hours post-infection. However, there was a suggestion of an inhibitory effect of 
kisspeptin-10 on selected pro- and anti-inflammatory cytokine expression, macrophage inflammatory 
protein (MIP)-1α, MIP-1β, tumour necrosis factor (TNF)-α, granulocyte macrophage colony stimulating 
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factor (GM-CSF) and interleukin (IL)-10, after 24 hours which was not observed at 6 days post-infection.  
Results from the whole blood stimulation assay suggested an inhibitory effect of kisspeptin-10 on 
selected LPS-induced pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) whilst generally not having an 
effect on selected anti-inflammatory cytokines (IL-10). Overall this study suggests, based on the lack 
of statistically significant data, a potential immunomodulatory effect of kisspeptin-10 based on the 
observed inhibition of pro-inflammatory cytokines. 
 
Investigating and developing an understanding of key regulators and mechanisms of maternal immune 
tolerance may help researchers understand the pathophysiological mechanisms underlying certain 
pregnancy-related disorders. This was a pilot study aimed at characterising the effect of kisspeptin 
stimulation on cytokines and chemokines responses. Manipulation of regulatory hormones such as 
kisspeptin could represent a potentially novel approach in the treatment of various pregnancy-related 
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Abbreviations and Symbols 
Listed here are all abbreviations used in this document multiple times 
 
 
ANOVA    analysis of variance  
APC    antigen presenting cells  
Arg-Phe-NH2   arginine-phenylalanine-amide (RF-amide)  
aTreg    adaptive T-regulatory cell 
BMI    body mass index  
(Ca2+)i    cytoplasmic calcium  
cAMP    cyclic adenosine monophosphate 
CAP18    cationic antimicrobial protein of 18 kDa  
cDNA    complementary deoxyribonucleic acid  
CD4+     cluster of differentiation 4  
CD8+    cluster of differentiation 8  
CD56+    neural cell adhesion molecule and cluster of differentiation 56 
CFU    colony forming units  
cm3    centimetres cubed 
CO2    carbon dioxide 
CREB    cAMP response element-binding protein  
CXC3C    chemokine receptor CXC3C 
CXCL14    chemokine CXC ligand 14 
oC    degrees Celsius 
DAG    diacylglycerol 
DC    dendritic cell 
dH2O    distilled water 
DMSO    dimethyl sulfoxide 
EDTA    Ethylenediaminetetraacetic acid 
EGF    epidermal growth factor  
EG-VEGF   endocrine gland derived vascular endothelial growth factor 
ELISA    enzyme-linked Immunosorbent Assay 
EVT    extravillous trophoblast  
FOXP3    Forkhead box P3  
FSH    follicle stimulating hormone 
g    grams 
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G-CSF    granulocyte-colony stimulating factor 
GM-CSF   granulocyte-macrophage colony-stimulating factor 
GnRH    gonadotropin-releasing hormone  
GPR54    G-protein receptor 54 (hOT7T175, KiSS1R or AXOR12) 
Gαq    heterotrimeric G protein q-alpha 
HBP/CAP37   heparin-binding-protein 
HGF    hepatocyte growth factor 
IDO    indoleamine 2,3-dioxygenase  
IFN    interferon  
IFN-    interferon-beta 
IFN-y    interferon-gamma 
IGFBP-1   insulin-like growth factor-binding protein 1 
IL    interleukin 
IL-1    interleukin-1 
IL-2    interleukin-2 
IL-3    interleukin-3  
IL-4    interleukin-4 
IL-5    interleukin-5 
IL-6    interleukin-6 
IL-8    interleukin-8 
IL-10    interleukin-10 
IL-11    interleukin-11 
IL-13    interleukin-13 
IL-15    interleukin-15 
IL-17    interleukin-17 
IL-17A    interleukin-17α 
IL-27    interleukin-27 
IP10    interferon gamma induced protein  
IP3     inositol 1,4,5-triphosphate 
IRM    idiopathic recurrent miscarriage  
iTreg    inducible T regulatory cell 
IUGR    intrauterine growth restriction 
Kiss1    kisspeptin 
Kiss1R    kisspeptin receptor 
KNDy    kisspeptin-neurokinin B-dynorphin  
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Kp-10    kisspeptin-10 
Kp-14    kisspeptin-14 
Kp-54    kisspeptin-54 
Kp-145    kisspeptin-145 
LH    luteinising hormone 
LIF    leukemia inhibitory factor 
LPS    lipopolysaccharides 
M    molar 
M-CSF    hematopoietic growth factor 
MCP-1    monocyte chemoattractant protein-1 
mg    milligram 
MIP1-A    macrophage inflammatory protein 1 alpha 
MIP1-B    macrophage inflammatory protein 1 beta 
mL    millilitre  
MOI    memorandum of incorporation  
mRNA    messenger ribonucleic acid  
Mtb    mycobacterium tuberculosis 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
[methylthiazolyl tetrazolium] 
NaHep    sodium-Heparin  
ng    nanogram 
NK    natural killer cells  
nm    nanometers 
OD    optical density  
PBMC    peripheral blood mononuclear cell 
PBS    phosphate-buffered saline 
pg    pictogram 
PIP2    phosphatidylinositol 4,5-bisphosphate  
PKC    protein kinase C  
PKA    protein kinase A 
PLC    phospholipase C  
pNK    peripheral natural killer cells 
P3    biosafety level 3 laboratory  
p234    peptide 234 
p356    peptide 356  
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RANTES   regulated upon activation normal T cell expressed and secreted 
RF amides   neuropeptide family  
RORyt    retinoic acid receptor-related orphan receptor gamma 
RPL     recurrent pregnancy loss  
RPMI-HEPES RPMI medium containing N-2-hydroxyethylpiperazine-N-
ethanesulfonic acid 
RSM    recurrent spontaneous miscarriage  
RT-PCR    Reverse transcription polymerase chain reaction 
SAv-HRP   streptavidin-horseradish peroxidase  
SDS    sodium dodecyl sulfate 
TGF-B    transforming growth factor beta 
TGF-B1    transforming growth factor beta 1 
Th    T helper  
Th1    T helper 1 
Th2    T helper 2  
Th17    T helper 17 lymphocytes  
TNF    tumour necrosis factor  
TNF-α    tumour necrosis factor alpha  
TNF-B    tumour necrosis factor beta  
uNK    uterine natural killer cell  
VEFG-C    vascular endothelial growth factor C  
vs    versus 
µg    microgram 




Chapter One General introduction 
1.1 Introduction 
 
Pregnancy is a fascinating event that researchers, to this day, do not yet fully understand. A unique 
and significant experience that is cherished around the world, pregnancy exists as a life changing event 
for many. However, not all pregnancies succeed and some progress uneventfully. Pregnancy-related 
complications may arise in the form of miscarriage, preeclampsia, intrauterine growth restriction 
(IUGR), preterm birth and unexplained recurrent spontaneous miscarriage (RSM) [1]. Causes of 
pregnancy loss include poor placentation, autoimmune disease, chromosomal abnormalities, 
exaggerated maternal immune response towards the fetus  and environmental factors. Globally, a 
significant portion of maternal and perinatal morbidity and mortality is due to such complications, 
especially in low and middle income countries [1,2,3]. The 2014-2016 Saving Mothers Report (Sixth 
report on the Confidential Enquiries into Maternal Deaths in South Africa) reported the top three 
causes of maternal deaths to be hypertensive disorders in particular preeclampsia (leading cause of 
direct maternal death in South Africa), obstetric haemorrhage and non-pregnancy related infections 
[4]. Researchers today are still unwinding the fascinating physiological and biological tapestry of 
pregnancy in order to understand the mechanisms underlying gestation and pregnancy-related 
complications. 
 
One of the fundamental requisites for a healthy pregnancy involves the development of physiological 
tolerance of the maternal immune system to the semiallogenic (sharing some but not all genes i.e. 
sharing genes of the father and mother) fetus [5,6]. The fetus presents similar susceptibility to rejection 
by the maternal immune system to that of a transplanted organ (xenograft), however it is not rejected 
throughout its development [6,7]. It is essential for certain changes in the maternal immune system to 
occur for the mother to tolerate fetal antigens during pregnancy.  
 
Previously described mechanisms associated with recurrent pregnancy loss (RPL) include: poor 
placentation, autoimmune disease, human lymphocyte antigen status, uterine abnormalities, 
hormonal problems, chromosomal abnormalities, an elevated BMI and infection [9,10,11]. However, 
in less than 50% of RPL, the aetiological mechanisms remain unknown [10,11,12]. It has been 
suggested that one underlying cause for the remaining proportion of idiopathic RPL or idiopathic 
recurrent miscarriage (IRM) may be attributed to a lack of maternal immune tolerance towards the 
fetus [13]. Understanding the mechanisms that drive gestation as well as the physiology of pregnancy 
has become a global effort, with the hope of elucidating novel interventions for the treatment of 
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pregnancy-related disorders. Investigating mechanisms behind the development of maternal immune 
tolerance is crucial for our understanding of pregnancy and pregnancy-related complications.  
 
1.2 Mechanisms of immune tolerance formation and the immunology of 
pregnancy 
 
It is essential for certain changes in the maternal immune system to take place for the mother to 
tolerate fetal antigens during pregnancy.  There are several mechanisms which play an integral role in 
the development of immune tolerance including the induction of the enzyme indoleamine 2,3-
dioxygenase (IDO) by antigen presenting cells (APC) which is responsible for the increase in the number 
of adaptive/inducible T regulatory cells (aTreg/iTreg). The increase in aTreg/iTreg results in the 
suppression of the immune response, the shift from T-helper lymphocyte (Th)1 cytokine subset to Th2 
and the significant decrease in the expression of interleukin-17 (IL-17) from Th17 cellsIL-17 is 
responsible for stimulating cytotoxic reactions [5,6,14,15,16]. 
 
During pregnancy the mother’s body undergoes significant changes to immune reactivity and energy 
metabolism, largely related to significant increases in peripheral blood hormones such as the steroid 
hormones; oestrogen and progesterone, and the protein hormones; kisspeptin, human chorionic 
gonadotropin and gonadotropin releasing hormone amongst many others [7].  It is known that 
hormones are important regulators of the functional activity of the immune system and immune cells 
[5,6,7], for example: progesterone previously been demonstrated to increase the cytokines produced 
by Th2 cells, resulting in the maintenance of pregnancy. Th2 cells are dominant within the decidua in 
early pregnancy in humans. The Th2 derived cytokines, IL-4 and IL-6, induce the release of hCG from 
trophoblasts and the hCG stimulates progesterone production from corpus luteum in pregnancy. 
Shirshev et al reported that the hormones secreted by the placenta, protect the fetus from the 
aggressive maternal immune response of the mother, emphasizing the immunomodulatory effects of 
these hormones [16].  
 
Cellular immunity is mediated by specific effector cells in concert with the cytokines they produce. Two 
functional subsets of Th cells are responsible for inducing different effector responses. Th1 cells induce 
several pro-inflammatory responses including cell-mediated cytotoxic and inflammatory reactions 
through the release of IFN-γ, TNF-α and IL-2 [8,17,18]. In contrast Th2 cells, which have been associated 
with anti-inflammatory responses and successful pregnancy outcomes, enhance the production of B 
cell antibodies through the release of cytokines: IL-4, IL-5, IL-6 and IL-10 [17,18]. It has been 
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acknowledged that Th1 dominant milieu has a deleterious effect in pregnancy based on the fact that 
some Th1-dependent effector mechanisms are significant role players in acute allograft rejection 
[10,24,25]. In contrast, the production of Th2-type cytokines seems to be central for the induction and 
the maintenance of allograft tolerance [17,19,20,21,22]. The development of maternal immune 
tolerance towards fetal alloantigens is thought to be secondary to the dominance of Th2-type 
immunity over Th1-type immunity during pregnancy [23]. Th1-type immunity has previously  been 
associated with RSM [24,25]. 
 
A recent study investigated macrophages and villous tissue isolated from placentas of normal 
pregnancies in the first and third trimesters [26]. The study established two groups of cytokine 
responses., The first was characterised by relatively low basal expression levels of IL-1,IL-6, IL-8, IL-10, 
and TNFα (which are major regulators of the inflammatory response) under normal physiological 
conditions whilst being highly inducible by  bacterial endotoxin such as LPS [26]. It was suggested that, 
in normal pregnancy, the cytokines mainly ensure protective responses to bacteria from placental 
macrophages [26]. The cytokines of the second group (IL-11, IL-17A, IL-17F, TGF-β, VEGF) were relevant 
to this study as they relate to spontaneous miscarriage and preterm birth [32,33]. Increased levels of 
TNF-α, IL-1β, IL-6, and IL-8 in the amniotic fluid [27,28,29] and cervicovaginal fluid [27,30,31] have been 
associated with preterm birth. 
 
There are several role players in the establishment of maternal immune tolerance and it is important 
to understand the mechanisms and factors regulating its development. Understanding the intricacies 
involved in maternal immune tolerance tenders an opportunity for better understanding of pregnancy-
related disorders. 
 
1.2.1 Cytokine production  
 
Trophoblastic and lymphomyeloid cells responsible for producing cytokines are present within the 
decidua. The main types of cells present include: T lymphocytes (CD8+), macrophages and natural killer 
(NK) (CD56+) cells [10,32]. Modulation and regulation of cytokine expression i.e. the type and/or 
quantity is as a result of intercellular communication. An alteration in, T cell produced, cytokine 
expression pattern may play an important role in the development of immunological tolerance and/or 
immune activation. T-helper (Th) cells can be grouped into classes: Th1 cells, which produce pro-
inflammatory cytokines, interleukin (IL) 2, tumor necrosis factor (TNF) α and interferon (IFN) γ, which 
play a role in cell-mediated immunity, and Th2 cells, which produce anti-inflammatory cytokines, IL-4, 
IL-5 and IL-13 and are involved in humoral immunity [33]. As reviewed by Jamieson et al, it was 
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Figure 1.1: Illustration of pro-invasive and anti-invasive paracrine factors essential for the regulation of 
implantation [34]. Abbreviations: IL-1 – interleukin - 1; IL-15 – interleukin - 15 ; HGF – hepatocyte growth 
factor  ; IGFBP-1 – insulin-like growth factor binding protein - 1  ; IL-6 – interleukin - 6; LIF - ; IL-11 – 
interleukin - 11 ; IL-8 – interleukin - 8; EGF – epidermal growth factor ; CXCL14 – chemokine ligand 14; 
CXC3C – fractalkine; CCL14 – chemokine lgand 14 ; TNF-α – tumor necrosis factor alpha ; TGF-β – 
transforming growth factor beta ; EG-VEGF – endocrine derived vascular epidermal growth factor; IFN-γ 
– interferon gamma.  
suggested that the suppression of cell-mediated immunity whilst maintaining humoral immunity, 
proved necessary for the development of maternal immune tolerance for fetal antigens [8]. Adaptive 
immunity comprises two types of immunity i.e. humoral immunity and cell mediated immunity. During 
adaptive immunity an antigen-specific immune response is generated. Humoral immunity is triggered 
by B cells while cell mediated immunity is triggered by T cells. The main difference between humoral 
and cell mediated immunity is that antigen-specific antibodies are produced in humoral immunity 
whereas antibodies are not produced in cell mediated immunity, whereby T cells destroy foreign 
molecules through phagocytosis. 
 
Stimulation of trophoblast cells and the influence of gestational hormones leads to, amongst others, 
the transformation of the endometrium to the decidua which through this same modulation becomes 
receptive to implantation. It is believed that development of maternal immune tolerance for the 
genetically foreign fetus is dependent on the interactions of a range of cytokines secreted at the site 
of implantation by maternal and fetal cells [8,10]. Development of the decidua from the endometrium 
is dependent on the presence of certain gestational hormones and stimulation of trophoblast cells 
which is partly regulated by kisspeptin. Communication between the decidua and trophoblast cells is 
mediated by cytokines and cell surface receptors [8,10]. Figure 1.1 higlights both pro- and anti-invasive 





















It has become evident that the cytokines associated with unsuccessful pregnancy outcomes include: 
IFN-γ, TNF-α and IL-2 which fall under T helper 1 (Th1) cells. Two functional subsets of Th cells include 
Th1 and T helper 2 (Th2) cells which are responsible for inducing different effector responses. Th1 cells 
induce several responses including cell-mediated cytotoxic and inflammatory reactions through the 
release of IFN-γ, TNF-α and IL-2 [8,17,18]. Th2 cells are conducive to pregnancy through primarily 
enhancing production of B cell antibodies through the release of cytokines: IL-4, IL-5, IL-6 and IL-10 
[17,18]. Therefore, during pregnancy there remains a Th2-bias, and a shift in the ratio towards Th1 
potentially results in adverse outcomes such as unexplained miscarriage. This bias was further 
validated by Raghupathy et al in the circulation of pregnant women, however it remains to be seen 
whether this immunological shift is present at the maternal-fetal interface [17]. It has been shown that 
the effects of cell-mediated immunity have deleterious consequences on the fetus during pregnancy. 
Yui et al demonstrated the effects of tumor necrosis factor (TNF-α) which induces apoptosis in human 
primary villous trophoblast cells whilst interferon (IFN)-γ enhances TNF-mediated cytotoxicity of these 
cells [17,35]. Supplementing this finding was that both the cytokines were shown to inhibit human 
trophoblast outgrowth in vitro [17,36]. An increased production of interleukin-2 (IL-2) and IFN-γ by 
peripheral blood mononuclear cells (PBMC)s along with a reduction in IL-10 have been associated with 
spontaneous miscarriage in humans [17,37]. In addition, it has been reported that in women with a 
history of unexplained recurrent spontaneous miscarriages, trophoblast antigens induce the release 
of embryotoxic cytokines (IFN-γ and TNF-α) by maternal PBMCs [17,38]. Moreso, et al showed that 
injection of IFN-γ or TNF-α or IL-2 induced abortion in normal pregnant mice [17,39]. 
  
A previous study has illustrated in recurrent spontaneous miscarriage (RSM) that the altered immunity 
is attributed to the Th1/Th2 hypothesis [40].  The fetus escapes maternally derived T-cell responses 
through alteration of Th1 differentiation toward Th2 pathway [40]. As a result, the pro-inflammatory 
effects of Th1-type immunity are suppressed/inhibited [10,41,42,43]. In contrast, there is an increased  
chance of RSM if Th0 differentiation is biased towards the Th1 pathway. However, it has been shown 
that immunity with a Th2 dominance has also been reported in cases of RSM therefore establishing 
that the Th1/Th2 balance is not singularly sufficient to explain the mechanism underlying the 
development of maternal immune tolerance for the fetus [44,45]. Previously it has been suggested 
that observed differences in cytokine production may be due to factors other than the presence of 
foreign fetal antigens such as infections during pregnancy, as infectious agents will alter the cytokine 




Another cellular subset, the CD4+ T lymphocytes (Th17 cells), secrete IL-17, a pro-inflammatory 
cytokine. Cells expressing IL-17 may induce inflammation during pregnancy and subsequently lead to 
miscarriage[14,47]. aTreg cells and Th17 are two individual lymphocytes subsets which functionally act 
in contrast to each other. Autoimmune responses are suppressed by aTreg cells and play a role in 
preventing fetal rejection. In contrast, Th17 cells promote transplant rejection and autoimmunity, and 
when numbers are elevated, may play a  role in recurrent spontaneous miscarriage [47,48]. In contrast, 
autoimmune responses are suppressed by aTreg cells and play a role in preventing fetal rejection. 
aTreg cells play significant roles in immunoregulation and induction of immune tolerance [10]. Previous 
studies have shown that aTreg cells inhibit cytokine production and proliferation of both CD4+ and 
CD8+ T cells, immunoglobulin production by B cells, cytotoxic activity of natural killer (NK) cells, and 
maturation of dendritic cells (DCs), which in turn may result in the development of immune tolerance 
[49,50]. Unexplained recurrent miscarriage may be a variation of Th1/Th2/Th17 and aTreg cell subsets 
[17,47,48]. Cytokine imbalances have profound effects on the Th1/Th2/Th17 balance.  
 
Robertson et al demonstrated the importance of IL-10 for pregnancy maintenance, presenting mice 
with an IL-10 knockout mutation that were more susceptible to inflammation-induced abortion [51]. 
Th17 induced inflammation is essential for successful placentation and may play a role in the 
protection of the uterine cavity against extracellular microbes, however, an excessive inflammatory 
response may lead to fetus rejection [52]. Together with TGF-β, IL-6 induces the development of Th17 
cells from undifferentiated T cells and additionally inhibits TGF-β-induced aTreg differentiation [47]. 
Interleukin-6, is multifunctional and plays a significant role in the context of this study i.e. immune 
adaptations which are necessary for the development of immune tolerance. Therefore, potential 
effects of kisspeptin on IL-6 warrant further investigation.  
 
Cytokines are imperative to the regulation of the immune system during pregnancy. It is crucial to 
maintain an appropriate cytokine balance at the maternal–fetal interface as well as in circulation. It 
has become evident that, during pregnancy, cytokines play a role in the control of immune response 
against fetal antigens. Unexplained recurrent miscarriage can potentially be a consequence of 
variation of Th1/Th2/Th17 and aTreg cells subsets [17,47]. These variations may underlie hypothesised 
mechanisms in pregnancy loss such as infections and autoimmune disorders.  
 
Based on the numerous roles played by selected cytokines in the development of maternal immune 
tolerance during pregnancy, it is important to investigate the effects of kisspeptin on all cytokines (pro- 
and anti-inflammatory) as this may have implications for understanding adverse pregnancy outcomes. 
Given the critical role of cytokines in altering the balance between Th1/Th2/Th17 cells and Treg cells, 
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should kisspeptin prove to be a major regulatory factor of these cytokines, this could provide the 
foundation for further investigation into its use as a potential intervention for various pregnancy-
related disorders, including preeclampsia and unexplained recurrent miscarriage. Kisspeptin-mediated 
effects on selected cytokines have been previously described as the inhibition of pro-inflammatory 
cytokine expression (IL-1β, IL6 and IL-17) whilst inducing the expression of anti-inflammatory cytokines 
(IL-10) [16]. However, the effect of kisspeptin on several immunomodulatory cytokines remains to be 
investigated.The study presented here investigated the effects of kisspeptin on the expression of 
cytokines induced by a pathogen and lipopolysaccharides (LPS) in order to establish the 
immunomodulatory characteristics of the hormone (if any) and subsequently gain some insight into 
kisspeptin-mediated effects on the previously described Th1/Th2/Th17 cytokine ratio.  
 
The cytokines investigated in this study are: interferon (IFN)γ, interleukin-10 (IL-10), interleukin-17A 
(IL-17A), interleukin-1β (IL-1β), interleukin-1α (IL-1α), interlukein-6 (IL-6), monocyte chemoattractant 
protein-1 (MCP-1), tumour necrosis factor (TNF)-α, macrophage inflammatory protein (MIP)-1α, MIP-
1β and granulocyte macrophage colony stimulating factor (GM-CSF). These were chosen based on their 
role in immune response and immune function during pregnancy. A summary of selected cytokines 
which possess immunomodulatory characteristics, including those investigated in this study, is 
































Haematopoiesis, co-stimulation of T cell, 
fibroblast proliferation, acute phase 
response 
IL-3 Th2 
Activated T cell, mast cell, 
NK cell 
Proliferation and differentiation of myeloid 
progenitor stem cell, prevention of apoptosis 
induction in macrophages 
IL-6* Th1/Th2 
T cell, monocyte, 
endothelial cells, mast cells 
Stimulate B cell for antibody production and 




Inhibition of pro-inflammatory cytokines by 
monocyte, granulocytes, inhibition of IL-2 
production by T cell, inhibition of antigen 
specific T cell activation 
IL-15 Th1 
Activated T cells and natural 
killer 
Regulates activation and proliferation of NK 
cells and T cells 
IL-17* Th1 Th17 T-cells Regulation of inflammation 
IFN-α Th2 Leucocyte 
Anti-proliferative action, immunoregulatory 
action 
IFN-β Th2 
Fibroblast, epithelial cell, 
endothelial cell 
Antiviral, MHC antigen upregulation, NK cell 
enhanced cytotoxicity, antimicrobial 
IFN-γ* Th1 
Monocyte, macrophage, 
dendritic cell, T cell, B cell 
MHC class II expression, macrophage and NK 
cell activation, Ig isotype selection 
G-CSF* Th1/Th2 Stromal cell, endothelial cell 
Proliferation and differentiation of 
macrophage progenitor cell 
M-CSF Th2 
Fibroblast, endothelial cell, T 
cell, monocyte, neutrophil 
Monocyte proliferation, differentiation and 
activation 
GM-CSF* Th1/Th2 
T cell, macrophage, 
endothelial cell, B cell 
Inhibit apoptosis of target, proliferation, 
differentiation and activation of granulocyte, 
macrophage lineage 
A chemokines Th1/Th2 
Monocyte, neutrophil, 
endothelial cell, epithelial 
cell 
Neutrophil chemotaxis and adherence, IL-6 
secretion 
B chemokines Th1/Th2 
Monocyte, fibroblast, 
epithelial cells, melanocytes 
Monocyte activation, basophil activation 
RANTES Th1 
T cell monocyte, NK cell, 
fibroblast, epithelial cell, 
endothelial cell 
T cell chemotaxis and proliferation, 
monocytic chemotaxis and activation, NK cell 
chemotaxis, modulation of macrophages, 
eosinophils, T cells 
TNF-α* Th1 Macrophages, T cell 
Cytotoxic for tumor cell, anti-viral, anti-
bacterial, ant-parasitic activity 
TNF-β Th1 Mast cell, platelet, fibroblast 






Recruitment of inflammatory cells, inhibition 




Regulation of monocytic/macrophage 
migration and infiltration 
Table 1.1: Summary of selected cytokines, subtype, source and function. These cytokines possess 
important immunomodulatory properties. All abbreviations and symbols used in this table can be found in 




1.2.2 Natural killer cells  
 
Natural Killer (NK) cells are immune cells that, via the release of cytolytic granules containing perforin, 
granzyme and granulysin, are capable of lysing the target cells. During pregnancy there are two subsets 
of NK cells: peripheral NK (pNK) cells and NK cells present in the uterine mucosa i.e. uterine NK (uNK) 
cells [54]. The two subsets are contrasting in function. Unlike their pNK counterparts,  uNK cells are 
not cytotoxic, rather they provide a suitable microenvironment in the decidua, making it stable and 
accommodating for the growing foetus whilst promoting normal placentation, vascular remodeling 
and trophoblast infiltration, all of which are critical for a healthy pregnancy [55]. Regulation is essential 
in order to inhibit the cytolytic function of uNK cells as these cells possess cytolytic activity which lead 
to the lysis of trophoblastic cells when activated. Their regulation is mediated by a balance between 
activating and killer inhibitory receptors (KIRs). 
 
Trophoblast invasion is regulated by several factors secreted by uNK cells. In vitro studies have 
reported that interleukin 15 (IL-15) stimulates the process while TNF-α and IFN-γ have the inhibitory 
roles [56]. According to earlier reports, NK cells are capable of producing Th1 and Th2 cytokines [57].  
 
Given the role played by kisspeptin with regards to regulation of cytokine expression, a connection can 
be made between the activity and regulation of uNK cells during the early stages of pregnancy and the 
development of maternal immune tolerance. The effect of cytokine modulation by kisspeptin may 
effect the functional activity of uNK cells depending on the cytokines effected.  
 





An idiopathic condition characterised by the development of new-onset hypertension and evidence of 
end-organ dysfunction normally after 20 weeks of gestation, preeclampsia, as a maternal disorder, 
develops in about 10% of pregnancies, and is a leading cause of maternal and perinatal morbidity and 
mortality [58,59]. As defined by the International Society for the Study of Hypertension in Pregnancy 
(ISSHP), hypertension is diagnosed at a systolic blood pressure greater than 140 mmHG and a diastolic 
blood pressure greater than 90 mmHG [58]. Preeclampsia is a significant and severe hypertensive 
disorder which may complicate pregnancy [58,60], and is one of the leading causes of maternal and 
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perinatal morbidity and mortality worldwide [61,62]. A defective maternofetal immune response may 
contribute to the development of pregnancy-related complications, such as bleeding complications 
during the first trimester, pregnancy-induced hypertension, preeclampsia, or preterm birth. GM-CSF 
could play a role in the preeclampsia pathogenesis [63]. Of several causes of a defective maternofetal 
immune response, one significant cause, with relevance to this study would be that there is a higher 
level of GM-CSF present in decidual cells in patients with preeclampsia if compared with normal 
pregnancy. The cytokines involved in preeclampsia, TNF-α and IL-1β, upregulate GM-CSF mRNA 
expression in cultured first-trimester human decidual cells [64,65]. Moreso, GM-CSF levels in blood 
and the ratio of GM-CSF:total protein levels present within the placenta, are significantly higher in 
preeclamptic pregnancies than in normal pregnancies [64,66].  
 
1.3.2 Recurrent Spontaneous Abortion (RSM) 
 
One rare pregnancy-related complication includes RSM. An estimated 1-3% of women suffer up to 
three or more consecutive miscarriages prior to 20 weeks’ gestation with these cases being termed as 
RSM or recurrent pregnancy loss (RPL) [10,67]. The etiology of less than 50% of RSM cases are known 
[10,68]. Several mechanisms have been previously described as known causes of RSM however, it has 
been suggested that one underlying cause for the remaining proportion of idiopathic RSM cases may 
be attributed to an exaggerated maternal immune response towards the fetus [46].   
 
It is known that some cases of idiopathic RSM are characterised by an  increased production of pro-
inflammatory cytokines such as TNF-α and IFN-γ and decreased levels of anti-inflammatory cytokines 
such as IL-10 within PBMCs [17,26,38,68]. Cytokine expression by the cells of the immune system 
(human lymphocytes) in periphery does not correlate with the response of immune cells at the 
materal-fetal interface (69,70). It is important to investigate the role played by other important 
immunomodulatory cytokines as this may prove important in determining pregnancy outcome. In 
addition, this may aid in the determination of whether the hypothesis that RSM occurs as a result of 
high level expression of pro-inflammatory cytokines is teneble. 
 
1.4 Kiss1 gene, kisspeptins and GPR54  
 
There is a specific group of peptide hormones characterized by an Arg-Phe-NH2 motif at their carboxyl 
terminus which bind to G protein-coupled receptors [1,71]. Collectively, the group of peptides has 
been suitably named RF-amides and these hormones are found in many different species from very 
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primitive species like crustaceans through to humans. One of the most important RF-amides is 
kisspeptin (Figure 1.2).  
 
Originally isolated from melanoma cells, the Kiss1 gene was initially described as a tumour metastasis 
suppressor gene and, thus, the originally indentified 54 amino acid peptide product of this gene was 
initially termed metastin. The group of peptides encoded by the Kiss 1 gene have since been renamed 
as kisspeptins. Several important physiological roles for the kisspeptins have also since been identified. 


















The kisspeptin peptide is synthesised as a 145 amino-acid polypeptide prior to posttranslational 
modifications (Figure 1.2) [1,74]. Proteolytic processing of the primary transcript results in several 
kisspeptin products which vary in length: kisspeptin-145 (Kp-145), kp-54 (metastin), kp-14, kp-13 and 
the smallest active cleavage product Kp-10 [75,76,77].  
 
Kisspeptins are the endogenous ligands for the 396 amino-acid G-protein-coupled receptor, GPR54 
(also known as hOT7T175, KiSS1R or AXOR12) [75,78,79]. Both Kiss1 and GPR54 mRNA are expressed 
centrally in the brain, spinal cord, and hypothalamus [78,80]. Peripherally, kisspeptins have been found 
to be expressed in the placenta, pituitary, testes, pancreas, liver, small intestine, skeletal muscle, 
kidney, and cardiovascular system [78,80,81,82]. Significantly, although molecular localization has 
Figure 1.2: Illustration of primary kisspeptin transcript prior to proteolytic procession [73]. 
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revealed limited kisspeptin expression in both periphery and brain, high expression has been measured 
in the placenta [72,74,76]. With relevance to this study, GPR54 has been found to be expressed my the 
cells of the immune system [5,16]. 
 
Upon stimulation of GPR54, the receptor activates intracellular Gαq/11 G proteins, which in turn 
activates the enzyme phospholipase C (PLC)β which catalyzes the hydrolysis of the membrane lipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) to two secondary messenger products; diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3) [1,7,75,76]. The production of IP3 and DAG leads to an 
increase in the concentration of cytoplasmic calcium (Ca2+ ([Ca2+]i)) with subsequent activation of 
protein kinase C (PKC) [83]. In addition, kisspeptin has been shown to increase the concentration of 
intracellular cyclic adenosine monophosphate (cAMP). The increase in intracellular cAMP is associated 
with the activation of protein kinase A (PKA) leading to the phosphorylation of cAMP response 
element-binding protein (CREB). The phosphorylation of CREB results in the transcription of cytokine 
genes and Forkhead box P3 (FOXP3), known to eliminate the suppressive potential of T cells and 
regulation of the immune response [7,84,85]. This mechanism has been illustrated and summarised in 
Figure 1.3. 
 
Since its discovery, kisspeptin has been extensively characterized and its role in immune tolerance will 
be the focus of this study.  Amongst kisspeptins, Kp-10 (structure: YNWNSFGLRF-NH2) exhibits the 
highest conservation amongst several species, is the smallest active cleavage product [86] and has 
been demonstrated to be most relevant in modifying trophoblast behaviour. This study therefore aims 
to investigate the potential immunomodulatory effect of Kp-10 by exploring its effect on cytokine 















Figure 1.3: Illustration summarising the mechanism of action of kisspeptin upon induction of its receptor 
GPR54. Kisspeptin/GPR54 signalling has been shown to mediate its effects via intracellular calcium mobilization 
[73]. KISS1R is a seven-transmembrane domain, Gq/11-coupled receptor. When kisspeptin binds its receptor, 
the intracellular portion of KISS1R activates Gq/11. The α-subunit of Gq/11 activates PLC, which subsequently 
cleaves PIP2 into IP3 and DAG. IP3 promotes intracellular Ca2+ release from the endoplasmic reticulum, while 
DAG activates a signalling by phosphorylating PKC. This activation induces the phosphorylation of ERK1/2 and 
p38. In addition, activation of KISS1R recruits arrestin- 1 and -2, which down-regulates and up-regulates 
phosphorylated ERK1/2 levels, respectively. The activation of KISS1R can also stimulate the phosphorylation of 
PI3K/Akt, and suppress the phosphorylation of PI3K/Akt by blocking the prometastatic chemokine receptor 
CXCR4 (the receptor for the chemokine stromal cell-derived factor 1) signaling. These signals act on downstream 
pathways, including NF-κB, MMPs and VEGF, to promote hormone secretion and apoptosis. In addition, these 
signals inhibit metastasis, migration, angiogenesis and proliferation. Abbreviations are as follows: DAG - 
diacylglycerol; ERK1/2 - extracellular signal-regulated kinase; IP3 - inositol 1,4,5-triphosphate; PI3K - 
phosphatidylinositol-3-kinase; MMPs - matrix metalloproteinases; NF-κB - nuclear factor-κB; PIP2 - 



























1.5 Kisspeptin and the hypothalamic, pituitary and gonadal axis 
 
Other essential functions of kisspeptin and its receptor includes their roles in reproduction, in 
particular, the regulation and functioning of the gonadotropic axis. This neuroendocrine axis integrates 
regulatory signals from the hypothalamus, pituitary and gonads comprising; hypothalamic 
gonadotropin-releasing hormone (GnRH), pituitary gonadotropins, luteinising hormone (LH) and 
follicle stimulating hormone (FSH) as well as sex steroids and peptides synthesized by the gonads 
[75,87]. The function of kisspeptin in pubertal development and reproduction is determined by its role 
in inducing secretion of GnRH in various species [75,88]. When Kp-10 was injected into pregnant rats, 
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Figure 1.4: A summary of the role of kisspeptin in the regulation of the GnRH axis [103]. Abbreviations: GnRH 
– gonadotropin releasing hormone; GnIH/RFRP-3 – gonadotropin inhibitory hormone/RF-amide related 
peptide 3; MSH – melanocyte stimulating hormone; LH – leutinising hormone; FSH  - follicle stimulating 
hormone.  
 
it was able to induce a 27- and 15-fold surge of LH levels on day 13.5 and 20.5 [87]. Several studies 
have shown that peripheral injection of kisspeptin can potently stimulate gonadotropin secretion in 
many non-human mammalian species including rats [89,90], mice [91,92], monkeys [93], sheep [94] 
and humans [95,96,97,98,99,100,101,102]. These observed effects are abolished by pre-
administration with a GnRH antagonist [89,90,93] suggesting that kisspeptin-induced gonadotropin 
secretion is mediated through a GnRH-dependent mechanism. Indeed it has been demonstrated that 
exogenous kisspeptin stimulates the firing of GnRH neurons in vitro. This demonstrates a regulatory 
effect of kisspeptin in pregnancy based on the regulation of pregnancy-related hormones through 




























Kisspeptin plays an imperative role in the initiation of puberty, regulation of adult fertility and in 
placentation during pregnancy [75,104,105]. Puberty and reproduction are regulated by kisspeptin 
through its effect on GnRH secretion. Kisspeptin, in concert with Neurokinin-B and Dynorphin, are 
major regulators of GnRH secretion by GnRH neurons in the hypothalamus [72,105,106]. Secretion of 
gonadotropins (LH and FSH) from the pituitary gland is activated through the direct stimulation of 
GnRH neurons by kisspeptin-neurokinin B-dynorphin (KNDy) neurons [71,89,107]. In humans, it has 
previously been shown that mutations in either the GPR54 or Kiss1 gene, or both, result in gonadal 
dysfunction, in particular, isolated hypogonadotrophic hypogonadism, infertility and failure to undergo 
puberty (all brought on through in-activating mutations) [101,108,109,110,111]. In contrast, patients 
with mutations leading to enhanced activations of the kisspeptin signalling pathway undergo 
precocious puberty (activating mutations) [112]. 
 
1.6 Kisspeptins in pregnancy 
 
Previously, it has been shown that hypothalamic Kiss1 mRNA increases as pregnancy develops 
[87,103]. It is important to note that circulatory kisspeptin concentrations increase throughout 
pregnancy and dramatically decreases post-delivery, which is in stark contrast to kisspeptin expression 
in placental tissue [113].  
 
From an embryological perspective, the placenta  originates from the trophectoderm layer of the 
blastocyst. The placenta is essential for gaseous exchange and nutrient transport from the mother 
across to the fetus [114,115]. Additional functions of the placenta include its crucial role in anchoring 
the developing embryo to the maternal tissues. Healthy pregnancy and fetal development is 
dependent on effective placentation. The decidua , the endometrial lining during pregnancy, consists 
of several layers which include: the decidua basalis and capsularis which underlie the placenta and 
form part of the placental bed and the decidua parietalis. The decidua parietalis is the innermost 
uterine layer (endometrial layer) in pregnancy. This layer has no overlying placenta and is devoid of 
trophoblast cells therefore plays little direct role in placentation [1]. Matjila, et al. [104], showed low 
levels of kisspeptin expression in the decidua basalis, in comparison to the placenta and decidua 
parietalis. However, they demonstrated that receptor (GPR54) expression was much higher in the 
maternal tissues, supporting the autocrine/paracrine functional hypothesis proposed by Bilban et al. 
[86]. Simultaneously peripheral and circulatory kisspeptin concentrations were compared to placental 
tissue expression levels in the context of preeclampsia [58] and reported that while circulatory levels 
were diminished, tissue expression was elevated in pregnancies complicated by preeclampsia. 
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Recently lower  circulatory kisspeptin levels in early pregnancy have been associated with an increased 
risk of spontaneous miscarriage [116]. In addition, circulating kisspeptin concentrations were found to 
be lower during early stages of pregnancy in women with a history of miscarriage, premature delivery 
and small-for-gestational-age neonates [116,117]. Additionally, low kisspeptin levels have been 
described in pregnancies with placental dysfunction such as gestational diabetes, preeclampsia, and 
intrauterine growth restriction [116]. 
 
Cetkovic, et al, showed that in pregnancies with type 1 diabetes and chronic hypertension, the mean 
plasma kisspeptin levels were significantly lower when compared with the healthy control group (p < 
0.001 in the first and second trimesters and p < 0.05 in the third trimester) [118].  The study also 
showed a decrease in plasma kisspeptin levels in the second and third trimesters which was found in 
patients with gestational diabetes (p < 0.001 in the second and third trimesters) and preeclampsia (p 
< 0.001 in the second trimester and p < 0.05 in the third trimester) [118]. In patients with preclampsia 
and placental dysfunction, they showed that low kisspeptin levels in the third trimester were 
associated with adverse perinatal outcome. Armstrong, et al., showed that serum kisspeptin levels 
were significantly lower in those women who subsequently developed preeclampsia than in healthy 
controls [median (quartile range) 1109 (449) vs 1188 (365) pg/mL, p = 0.029] and in those with intra-
uterine growth restriction [1164 (386) vs 1188 (365) pg/mL, p = 0.016] [119].  
 
Further investigation may advance our knowledge on the role of kisspeptin in the establishment of the 
placenta and knowledge of the mechanisms underlying placentation. It is important to compare the 
expression levels of kisspeptin in the periphery (serum) during the early stages of pregnancy, 
comparing healthy pregnancies with pregnancies with a history of RSM or other pregnancy related 
disorders. This is important when investigating the development of maternal immune tolerance 
formation during pregnancy. 
 
1.7 Kisspeptin and trophoblast invasion 
 
Placentation can be described as a process involving, amongst others, adequate trophoblast invasion, 
transformation of the spiral arteries from high resistance low capacity vessels to low resistance high 
capacity vessels as well as adaptation of the maternal decidua, all of which are crucial for successful 
pregnancy [104]. Insufficient transformation of the spiral arteries correlates with poor pregnancy 
outcomes such as preeclampsia and IUGR [120,121]. Spiral arterial transformation is dependent on the 
efficiency and level of endovascular invasion of extravillous trophoblast (EVT) cells. GPR54 is expressed 
in EVT cells whereas both kisspeptin and its receptor are expressed in villous trophoblast cells [75,104]. 
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The Kiss1 gene and GPR54 have been identified to play a major role in trophoblast invasion and 
migration as reported by several studies [86,104,122].  
 
The importance of kisspeptin and GPR54 in trophoblast invasion was demonstrated by comparing 
mRNA signatures between the first and third trimesters whereby Bilban et al found abundant 
expression of Kiss1 and GPR54 transcripts in the first trimester, a period where invasive capacity and 
migration efficiency is most important [86]. The study also highlighted that the smallest modified 
product of the Kiss1 gene, Kp-10, inhibited trophoblast invasion. In addition to the role kisspeptin plays 
in invasion inhibition, kisspeptin has been implicated in the regulation of genes involved in matrix 
degradation and angiogenesis, both being crucial processes in placentation [123,124]. Following 
implantation, the supply of nutrients and oxygen to growing foetus is essential [125]. Trophoblast and 
uterine natural killer (uNK) cells [126] promote the transformation of endometrial vessels and spiral 
arteries into high capacity and low resistance vessels allowing adequate supply of blood and nutrients 
from mother to foetus [127].  
 
Previously it has been shown that kisspeptin inhibits trophoblast invasion in vitro [58,86,128]. In 
healthy pregnancies the concentration of kisspeptin in serum significantly increase as pregnancy 
progresses and considerably decreases post-delivery [113,116]. In contrast, expression of both Kiss1 
and GPR54 transcripts in the placenta are highest in the first trimester (suggesting a role for regulation 
of invading trophoblasts) and lowest at term [129,130]. Decreased serum levels of kisspeptin, during 
early pregnancy, may be associated with an increased risk of spontaneous abortion [116]. 
Furthermore, it has been found that during the early stages of pregnancy, circulating concentrations 
of kisspeptin were found to be lower in women who had miscarriage, preterm delivery, small-for-
gestational-age neonates, or intrauterine growth retardation [116,131]. Therefore, it can be suggested 
that kisspeptin may play a pivotal role in successful placental and fetal development.  
 
1.8 Kisspeptin and maternal immune tolerance formation 
 
Gorbunova et al reported that the recently discovered peptide hormone, kisspeptin, increased the 
formation of active aTreg cells [7]. In addition, the study found that kisspeptin decreased the 
expression of the pro-inflammatory cytokine, IL-17, through the inhibition of Th17 cell differentiation 
and concurrently, decreased IL-17A secretion by CD4+T cells regardless of kisspeptin concentration [5]. 
Liu et al suggested that human Th17 cells play a major role in rejection of fetal antigens and as a result 
may be deleterious to pregnancy [14]. The same study maintained that aTreg cells were beneficial to 
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the outcome of pregnancy, highlighting the importance of the ratio of aTreg/Th17 during pregnancy 
which plays an important role in the development of maternal immune tolerance to the fetus [7,14]. 
The shift of ratios of aTreg/Th17 towards aTreg is a major mechanism of immune tolerance stability 
during pregnancy [47,48]. Therefore, tight and specific hormonal regulation of aTreg cell numbers, 
functional activity and homeostasis in vivo is suggested as one of the most important factors 
contributing to the mechanisms of developing maternal immune tolerance to the fetus during 
pregnancy [47]. 
 
Cells expressing increased levels of IDO can additionally contribute to the generation of aTreg and the 
subsequent activation of IDO leads to the death of cytotoxic T lymphocytes due to the absence of 
sufficient levels of tryptophan [14,16]. Mellor et al reported the reaction catalysed by IDO, whereby 
tryptophan is consumed and degraded into toxic products such as kynurenine which was shown to 
effect the activity of cytotoxic T lymphocytes [15]. This is significant as kisspeptin does not only elicit 
an effect on the ratio of aTreg/Th17, but the hormone is also responsible for the increased induction 
of IDO by monocytes during the second trimester of pregnancy, the most sensitive period for 
miscarriage [16]. The increased induction of IDO by kisspeptin results in the suppression of the immune 
response based on the increase in aTreg cells and decrease in IL-17 producing Th17 cells. 
 
It has been demonstrated that IL-27 may regulate the expression of Th17 and aTreg cells in women 
with recurrent spontaneous miscarriage [132]. The study showed that IL-27 induced IL-10 production 
by both CD4+FOXP3- and CD4+FOXP3+ cells which subsequently promotes the differentiation of IL-10 
secreting aTreg cells and inhibits Th17 differentiation [132]. It has been reported that the 
downregulation and loss of function of aTreg cells including low expression of FOXP3, IL-10 and TGF-β 
leads to an increase in the development of preeclampsia and spontaneous abortion [5,133]. In 
conjunction with the effects of IL-27, kisspeptin enhances the expression of FOXP3 
(aTreg/CD4+FOXP3+) and IL-10 whilst suppressing the expression of IL-17 and RORγt (inhibits 
production of Th17 cells/CD4+RORγt+ cells) [16].  The role of kisspeptin in cytokine regulation cannot 
be underplayed as kisspeptin enhances the secretion of IL-10 by CD4+ T lymphocytes primed with 
transforming growth factor (TGF)-β1 which contributes to the decrease of IL-17A secretion by CD4+ T 
lymphocytes primed with IL-1β/IL-6 [16].  
 
It is important to note that the inflammatory phenotype of macrophages presented in the early stages 
of pregnancy is attenuated and increases with the progression of pregnancy [27]. Pavlov et al, reported 
that the low basal but inducible cytokines levels are possibly modulated by kisspeptin during 
pregnancy, especially during infection. Cytokines in the second group which are constitutively 
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expressed and not responsive to LPS stimulation [27], may be regulated by kisspeptin due to their 
constant expression, however, these findings need further investigation.  
 
It has been shown previously that kisspeptin is an essential regulator of monocyte function during 
pregnancy [134], therefore the hormone may be critical for the formation of immune tolerance to 
antigens of the semiallogenic fetus. Based on this, there is adequate evidence suggesting that 
kisspeptin and its cognate receptor, GPR54, play key roles in immune regulation during pregnancy and 
these roles are further investigated in this study. If a role of kisspeptin is established based on the 
findings of this study, this may lead to a better understanding of how maternal immune tolerance is 




Kisspeptin has been well described in terms of its role in regulating puberty onset and trophoblast 
invasion in pregnancy. There is evidence implicating kisspeptin and its cognate receptor, GPR54, as 
important role-players in immune regulation during pregnancy and this study aims to extend existing 
knowledge. 
 
Investigating and developing an understanding of key regulators and mechanisms of maternal 
tolerance development may help us understand certain pregnancy related disorders and how to 




This study hypothesised that kisspeptin alters the expression of anti-and pro-inflammatory cytokines 




To determine the immunomodulatory effects of kisspeptin using peripheral blood mononuclear cells 
(PBMCs) and whole blood from healthy and non-pregnant, women, using in vitro PBMCs and  whole 








1. Investigate the regulation of cytokines by kisspeptin in PBMCs of healthy and non-pregnant 
women using an in vitro infection assay. 
 
2. Investigate the regulation of cytokines by kisspeptin in PBMCs of healthy non-pregnant women 
using an in vitro whole blood LPS stimulation model. 
 
These experiments will serve as the basis for an in vitro proof-of-concept model for future in vitro 
experiments on pregnant women with a history of idiopathic recurrent miscarriage to determine the 
immunomodulatory properties of kisspeptin in pathological states.   
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Chapter Two METHODS AND MATERIALS 
2.1 Reagents 
 
Unless otherwise indicated, all chemicals and solvents used in this study were purchased from Sigma 
Aldrich, Merck or Thermo-Fischer Scientific (South Africa). Kisspeptin-10 (Kp-10) and Peptide 356 
(p356) were obtained from EZbiolabs (USA) whilst Lipopolysaccharides (Escherichia coli O55:B5, CAT. 
NUMBER: L4005) was obtained from Sigma-Aldrich.  
 
All solutions prepared in the laboratory are detailed in Appendix A. 
 
2.2 Ethics statement 
 
Initial tests (PBMC infection assay) were conducted in collaboration with the Immunology Research 
Group, Division of Molecular biology and Human Genetics, Faculty of Medicine and Health Sciences, 
Stellenbosch University, South Africa.  
 
Ethics for this study was approved by the Human Ethics Committee of the Faculty of Health Sciences, 
University of Cape Town (REF-4412019). Approval for research at Stellenbosch University was granted 
by the Health Research Ethics Committee of the Faculty of Health Sciences, Stellenbosch University 
(ref: N13/05/064A). The recruitment procedure and ethics was included in an existing project within 
the ALERT study of the Immunology Research Group at Stellenbosch University. Recruitment to the 
study was conducted by members of the research team at the University of Cape Town and 
Stellenbosch University, respectively.  
 
A written informed consent was obtained from all study participants. The patients were counselled 
about the study in their preferred language. Patient comprehension of the details of the study was 
ensured  before enrolment and sample collection. Therefore, enrolment was based on the patient’s 
willingness to participate in the absence of any coercion. Refusal to participate in the study did not 






2.3 Study participants  
 
Patient inclusion criteria for the study were as follows: 
 
Healthy non-pregnant women of reproductive age (18-35 years old) with no history of recurrent 
miscarriage, previous pregnancy complications or known medical disorders.  
 
Patient exclusion criteria for the present study were as follows: 
 
1. Women below the age of 18 and above the age of 35 years.  
 
2. Women with known underlying medical conditions such as autoimmune, endocrine or 
thrombophilic conditions.  
 
Healthy non-pregnant women were recruited from both community health clinics, Groote Schuur 
hospital and Tygerberg Hospital.  
 
2.4 Peripheral blood mononuclear cell (PBMC) infection assay 
 
2.4.1. Tissue sampling and collection  
 
Fractionated suspensions of PBMCs were used. PBMC are comprised of monocytes and lymphocytes 
and included any perioheral blood cell that has a round nucleus. Blood was obtained from 5 healthy 
non-pregnant women of reproductive age via venepuncture (Tygerberg Hospital, Stellenbosch 
University, South Africa). 54 ml of blood was collected from each patient in 6 x 9 ml sodium-heparin 
(NaHep) tubes for subsequent PBMCs isolation. 
 
PBMCs were isolated using Ficoll-Paque Plus (GE Healthcare, Lifesciences, USA) density gradient 
centrifugation (1.077 g/cm3). The isolation procedure involved carefully layering (pipetting) 35 ml of 
blood from NaHep tubes diluted (1:1) in phosphate-buffered saline (PBS) (Appendix A) onto 15 ml of 
Ficoll-Paque Plus within a 50 ml conical tube. Following this, without disturbing the Ficoll layer, cells 
were centrifuged at 400 x g for 25 minutes at room temperature (no brake). Once complete, the yellow 
plasma layer was carefully aspirated and discarded and the thin white PBMC layer was removed and 
placed into a 50 ml conical tube. Cells were then washed with PBS (made up to 50 ml) and centrifuged 
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at 600 x g for 4 minutes at 4 °C (no brake). Cells were then washed again with ice cold PBS (made up 
to 50 ml) and centrifuged at 150 x g for 8 minutes at 4 °C (no brake). The supernatant was carefully 
removed and cells were resuspended in 5 ml of AIM-V medium (serum-free)  (ThermoFischer Scientfic, 
South Africa) for subsequent cell counting (see Section 2.4.2). Cell viability of each suspension was 
evaluated employing Trypan blue manual cell counting and only batches with a cell viability between 
90%-98% were used for further investigations. Note: if there was a high degree of red blood cell 
contamination on top of the PBMC pellet, an optional red blood cell lysis step was conducted prior to 
resuspension in AIM-V media which included: resuspending the pellet in 5 ml of sterile 1X ammonium-
chloride-potassium lysis buffer (Appendix A); incubating the pellet for 3-5 minutes; adding 10 ml of ice 
cold PBS and centrifuging the cells at 400 x g for 10 minutes at room temperature. After isolation and 
counting, cells were then suspended in AIM-V medium at 1 x 106 cells/ml.  
 
2.4.2. Cell counting 
 
For counting purposes, 10 µl of resuspended cells was added to 90 µl Trypan blue (1:10 dilution in 
PBS), and 10 µl of the resultant mixture was pipetted onto a Neubauer haemocytometer slide 
(Marienfeld) and covered with a cover slip. Trypan blue allows for the identification of live cells through 
staining of dead cells, therefore allowing differentiation of live cells from dead cells whereby live cells 
were counted using a microscope (Nikon TMS). 
 
To determine cell concentration and the volume of cells needed for seeding, the following formulae 
were used: 
 
Cell concentration: 𝐶𝑒𝑙𝑙𝑠/𝑚𝑙 =
# 𝑐𝑒𝑙𝑙𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑 𝑖𝑛 4 𝑠𝑞𝑢𝑎𝑟𝑒𝑠 𝑜𝑓 ℎ𝑒𝑚𝑜𝑐𝑦𝑡𝑜𝑚𝑒𝑡𝑒𝑟
4
 × 10 × 10 000 
 
Seeding: 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙) =
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑙𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 (𝑝𝑒𝑟 𝑚𝑙)
 
 
2.4.3. Mycobacterium tuberculosis (Mtb) preparation  
 
5X H37Rv Mtb stocks were prepared by diluting Mtb (Stellenbosch University, South Africa) in 7H9 
medium (Appendix A) to obtain a final concentration of 2.5 x 106 Colony Forming Units (CFU)/ml. 
Thereafter a working stock was prepared by diluting the 5X Mtb stock (2.5 x 106 CFU/ml) in AIM-V 
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medium to obtain a final concentration of 5 x 105 CFU/ml (1 x105 CFU/well, multiplicity of infection 
(MOI) of 5:1).   
 
2.4.4. PBMC infection and kisspeptin treatment 
 
This assay was designed to determine the effects of kisspeptin on cytokine expression following PBMC 
infection/stimulation. Initial stimulation experiments with 5 healthy and non-pregnant patients were 
conducted at the Division of Molecular biology and Human genetics, Immunology Research Group 
Stellenbosch University, South Africa.  The Biosafety level 3 laboratory (P3) was utilised as well as an 
existing and optimised model for Mycobacterium tuberculosis (Mtb) infection (described below). 
 
PBMCs were seeded at 4 x 105 cells and cultured overnight in screw-top (with O-ring) Eppendorf tubes 
(Lasec, South Africa) at 37°C in 5% CO2 in the absence or presence of treatment i.e. the positive control 
(Mycobacterium tuberculosis [Mtb] infection only and no hormonal treatment); negative control (no 
infection and no hormonal treatment); antagonist (alone) p356 at 10-6 M; Kp-10 (alone) at 10-6 M; Kp-
10 + p356 both at 10-6 M; Kp-10 (alone) at 10-9 M and Kp-10 at 10-9 M + p356 at 10-6 M. All hormonal 
treatments were stimulated via Mtb infection. The solvent i.e. distilled water, was used as a control 
for treatment. Stimulation/infection experiments were conducted following overnight incubation. 
 
Following overnight incubation, 400 µl of PBMC samples were centrifuged at 250 x g for 5 minutes 
before the media was removed and thereafter washed with RPMI-HEPES media (Sigma Aldrich). Mtb 
infection took place for 2 hours in the absence or presence of fresh treatment (with or without Kp-10 
and antagonist p356). Cytokines were harvested at 3 different time points following infection i.e. 2 
hours (immediately after infection), 24 hours (1 day) and 144 hours (6 days). Uninfected and untreated 
samples were used as the negative control whereby 7H9 media (Appendix A) was used as the control 
for infection. Cells were incubated for two hours at 37°C in 5% CO2 in the presence or absence of Mtb 
at an multiplicitiy of infection (MOI) of 5:1 with treatment. 
 
Processing at the end of each time point was conducted as follows: cells were centrifuged at 250 x g 
for 5 minutes. Once the cells had been pelleted, the supernatants were collected and centrifuged at 
maximum speed (600 x g) for two minutes. Harvested supernatants were then filter sterilized using 
syringe driven Millex-GV filter units and stored at -80°C for subsequent cytokine analysis via Luminex. 
For the time points, 24 hours and 144 hours, AIM-V medium was replenished containing the respective 
treatments. Following the 2 hour infection process and samples were incubated at 37°C at 5% CO2 until 
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harvesting. Full media (including treatment) was replenished for the 144 hour time point again at 72 
hours (day 3) and all samples were re-treated with/without hormone every day from infection until 
harvest. 
2.4.5. Mtb plating procedure, in order to determine Mtb uptake employing colony forming 
unit (CFU) counts  
 
After the harvesting of supernatants (Section 2.4.4.) the cell pellet was lysed by adding cold sterile 
dH2O containing 0.05% sodium dodecyl sulphate (SDS) (Appendix A) for 5 minutes at 4°C. Thereafter 
cells were transferred to a clean Eppendorf tubes containing 7H9 medium, used to neutralize the 
effects of SDS. Lysates were plated in serial dilutions (0 = stock; -1 = 10X dilution; -2 = 100X dilution; -
3 = 1000X dilution and -4 = 10 000X dilution all made up in 7H9 media) onto 7H11 agar plates (Appendix 
A) supplemented with BD DifcoTM BBLTM Middlebrook OADC Enrichment media (Fishcer Scientific) and 
sealed for incubation at 37°C with 5% CO2 for four weeks. The number of viable bacteria was 
determined after four weeks, post incubation, and represented as CFU/ml. 
 
2.5 MTT cell proliferation/viability assay  
 
PBMC were cultured overnight in screw-top (with O-ring) Eppendorf tubes and treated with the 
respective test compounds (Kp-10 and p356 or the solvent control (dH2O)) for the different time points 
i.e. two hours, 24 hours and 144 hours (Section 2.5). Processing of cells at each time point included the 
removal of cell culture supernatant and the addition of 40 µL of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide [methylthiazolyl tetrazolium]) and 360 µL of AIM-V medium for 4 hours 
of incubation. The MTT and medium was removed following incubation and the remaining formazin 
crystals were dissolved using 200 µl of dimethyl sulfoxide (DMSO). Thereafter, the absorbance was 
measured via a spectrophotometer at 595 nm. The fold increase was plotted relative to the solvent 
control (dH2O). 
 
2.6 Whole blood stimulation assay  
 
2.6.1. Tissue sampling and collection 
 
Blood was obtained from  healthy and non-pregnant women of reproductive age via venepuncture 
(Tygerberg Hospital, Stellenbosch University and Groote Schuur Hospital, University of Cape Town, 
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South Africa). 45 ml of blood was collected from each patient in 5 x 9 ml Ethylenediaminetetraacetic 
acid (EDTA) tubes or in 5 x 9 ml Sodium Heparin (NaHep) tubes. 
 
2.6.2. Optimisation of LPS stimulation model and final assay design 
 
Whole blood obtained from patients was placed into screw-top (with O-ring) Eppendorf tubes at 1ml 
of whole blood per tube. In order to test the effects of Kp-10 on LPS-induced cytokine expression, the 
whole blood stimulation model had to be optimised and established. TNF-α was the cytokine measured 
through the optimisation process via ELISA anaylsis.  
Firstly, it was important to establish the best time for LPS stimulation and the optimum LPS 
concentration needed for sufficient stimulation of cytokine expression. LPS was  solubilised in PBS to 
obtain a working solutions of 10 mg/ml. Further dilutions to 100 µg/ml and 1 µg/ml were made in PBS. 
Whole blood collected in EDTA tubes was stimulated with LPS for 4 hours, 12 hours and 24 hours using 
different concentrations of LPS, 10 µg/ml and 100 µg/ml (high concentrations were used to exaggerate 
a cytokine response). It was decided that 4 hours was the best time for LPS stimulation and the next 
step in the optimisation process included the use of more appropriate titrations of LPS concentrations 
(1 µg/ml, 100 ng/ml and 10 ng/ml) and a 6 hour stimulation time point in conjunction with a repeat of 
the 4 hour stimulation time point for validation purposes. It was ultimately decided to make use of a 4 
hour LPS stimulation time at a LPS concentration of 10 ng/ml. 
 
Subsequent optimisations included the optimisation of kisspeptin pre-incubation time. Whole blood 
was pre-incubated with treatment for 4 hours, 6 hours, 8 hours and 24 hours. Treatment included a 
treatment of the cells with Kp-10 at 1 µM to exaggerate a kisspeptin-induced response and a Kp-10 
titration (1 µM to 1 nM) in order to characterise the effect of Kp-10 at different pre-incubation times. 
Whole blood was stimulated with LPS at 10 ng/ml for 4 hours following pre-incubation. 
 
In conclusion, the final assay design used in this study was a 8 hour pre-incubation with Kp-10 
treatment (a kisspeptin titration from 1 µM to 1 pM) followed by a 4 hour LPS stimulation at 10 ng/ml. 
Supernatants were then harvested for protein expression analysis.  
Different blood collection tubes were tested in order to investigate if it had any influence on the 
results. Whole blood collected in NaHep tubes was subjected to the previously described assay design 
as well as the addition of a separate 24 hour pre-incubation experiment which was followed by a 4 
hour LPS stimulation at 10 ng/ml. It was decided to do longer pre-incubation time points to enhance 
cellular reactivity with the Kp-10 treatment based on the results of the intial experiments using NaHep 
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tubes. Whole blood collected in NaHep tubes was treated with Kp-10 (titration from 1 µM to 1 nM) for 
24 hours, 48 hours and 72 hours prior to being stimulated with LPS at 10 ng/ml for 4 hours. Cells were 
replenished with treatment every 24 hours. 
 
After the indicated treatment times, cells were centrifuged at 1 000 x g for 10 minutes and the 
supernatant was removed and stored in -80°C for cytokines analysis via ELISA at a later stage.  
 
2.7 Protein expression analysis 
2.7.1. Luminex assay  
 
Cell culture supernatants were harvested as previously described in Section 2.4.4. all Once the samples 
had thawed, supernatants were centrifuged at 600 X g for 10 minutes at 4°C to remove any debris or 
floating cells that may have been collected.  
2.7.2. Luminex assay protocol 
 
The supernatants were assayed to determine the concentrations of the following cytokines: IFNγ, IL-
10, IL-17A, IL-1β, IL-1α, IL-6, MCP-1, TNF-α, and MIP-1α, MIP-1β and GM-CSF. The cytokine 
concentrations present in the supernatant obtained from the PBMC infection assays were assayed 
using a luminex  MilliPlex® 27 plex MAP Human Cytokine/Chemokine Magnetic Bead Panel (cat #: 
HCTYOMAG-60K, Merck, South Africa) via the Bio-Plex 200 machine (BioRad, South Africa) according 
to the manufacturer’s instructions (Appendix B). Depending on choice, the assay was customized to 
detect specific cytokines from a minimum concentration of 0.06 ng/ml to 100 ng/ml (Linear range 0.06-
0.8 ng/ml) with an inter-assay and intra-assay variability of <15% and <10% respectively. Absorbance 
was read on a microplate reader at 450 nm. A standard curve constructed from relative absorbance 
versus concentration of the standard solutions was plotted and the concentrations of cytokines within 
the various samples were calculated from the standard curve. 
 
2.7.3. Enzyme-linked Immunosorbent Assay (ELISA)  
 
Cell culture supernatants were harvested as previously described in Section 2.6.2. Once the samples 
had thawed, supernatants were centrifuged at 600 X g for 10 minutes at 4°C to remove any debris or 
floating cells that may have been collected. The supernatants were assayed for the following cytokines: 





A 96-well high-binding Nunclon Delta treated ELISA plate (NuncTM MicrowellTM  96-well microplates) 
was coated with 100 µl of capture antibody (1:250) diluted in ELISA Coating Buffer (refer to Appendix 
A for composition). The plate was sealed and stored at 4°C overnight. Following overnight incubation, 
the wells were aspirated and washed 3X with ≥ 300 µl ELISA Wash Buffer (Appendix A). The wells/plate 
were blocked using 200 µl ELISA Assay Diluent (Appendix A) and sealed at room temperature for 1 
hour. The plate was then washed 3X with ELISA Wash Buffer. ELISA standards were prepared as 2-fold 
serial dilutions in Assay Diluent, specific to the cytokine of interest. The following were the ranges of 
concentrations for each cytokine: 250 pg/ml – 0 pg/ml for IL-1β, 500 pg/ml – 0 g/ml for IL-10 and TNF-
α and 300 pg/ml – 0 pg/ml for IL-6. Blank Assay Diluent served as the zero standard for the assay (0 
pg/ml). Eight standards were prepared in total. Wells were then loaded with 100 µl of standard or 
sample, in duplicate, sealed and incubated for 2 hours at room temperature. The plate was then 
washed 5X with ELISA Wash Buffer which, 100 µl of Working Detector (Detection Antibody at 
kit/cytokine-specific concentration and streptavidin-horseradish peroxidase (SAv-HRP) (1:250) reagent 
diluted in Assay Diluent) was added to each well, sealed and incubated for 1 hour at room temperature. 
The plate was then washed 7X using ELISA Wash Buffer with each wash consisting of 40 second soak 
in wash buffer. After the final wash step, 100 µl of Substrate Solution was added to each well (TMB 2-
component Microwell Peroxidase substrate, cat.number: 5120-0053, SeraCare) and incubated in the 
dark for 30 minutes. The enzyme reaction was stopped using 50 µl of ELISA Stop Solution – 2N H2SO4 
(Appendix A).  Once all bubbles were removed, absorbance was measured using a microplate 
spectrophotometer reader (GloMax® Discover System, Promega) at 450 nm with a lambda correction 
of 560 nm (within 30 minutes of stopping the reaction). Protein concentration of samples was 
determined by plotting the concentration of the standards against the corresponding optical density 
(OD) reading to generate a standard curve.  
2.8 Statistical analysis: 
  
A paired t test was used to compare baseline cytokine expression to LPS/Mtb stimulation of cytokine 
secretion with and without kisspeptin and antagonist, in whole blood or PBMC of healthy participants.  
 
 A linear regression analysis between the variables was performed and the best fit curve drawn on the 
data points. One-way analysis of variance (ANOVA) followed by Dunn’s multiple comparison test were 
performed to compare the differences across all the different participant categories. GraphPad Prism 
(version 5.00 for Windows, GraphPad Software, San Diego California USA, www.graphpad.com) was 
used for all analysis. A p < 0.05 defined statistical significance, where *, **, *** denotes p < 0.05; p < 
0.001 and p < 0.0001 respectively. 
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Chapter Three  Results 
 
3.1 Determination of the effect of Kp-10 on Mtb induced expression of MIP-1α, 
MIP-1β, TNF-α and GM-CSF in PBMCs of non-pregnant and healthy women  
As this is a pilot study, the first step of this investigation was to establish whether kisspeptin-10 (Kp-
10) had an effect on cytokine release in response to an infection, employing human PBMCs infected 
with Mtb as a model system. The model used was an established in vitro system utilising blood taken 
from 5 healthy (non-diabetic with no history of pregnancy-related complications) and non-pregnant 
women in sodium heparin (NaHep) blood collection tubes. The patient data in Table 3.1 displays the 
patient code number, sample collection time, sample date, patient age, date of birth and HbA1C value 
(average blood glucose levels for past two to three months i.e. indicator of diabetic status). 54 ml of 
blood was collected from each woman and PBMCs were isolated and subjected to Mycobacterium 
tuberculosis infection in the absence or presence of Kp-10 and kisspeptin antagonist, peptide 356 
(p356) treatment. Following infection, cell culture supernatants were collected at 2 hours, 24 hours 
and 6 days, and subjected to a Luminex multiplex assay to determine the level of several cytokines.  
 







D.O.B Age Gender 
HbA1c 
(POC) 
A386 2018/06/18 8:43 1970/05/19 48 Female 5.6 
A387 2018/06/25 8:37 1994/10/19 24 Female 5,9 
A388 2018/07/02 8:50 1994/08/19 24 Female 5,4 
A389 2018/07/23 8:50 1996/10/11 22 Female 5,5 







3.1.1 in vitro PBMC infection assay  
 
Protein expression analysis on selected cytokines employing a PBMCs infection assay with Mtb was 
performed on the 5 patients in order to determine the effect of Kp-10 on Mtb-induced immune 
response. PBMCs isolated from the women were infected with Mtb (MOI of 5:1) in the absence or 
presence of treatment with kisspeptin and its antagonist, p356  for the following time points: 2 hours, 
24 hours and 6 days (in the case of 6 day treatment, Kp-10 and p356 treatment was replenished every 
24 hours). Treatment included: uninfected and untreated negative control, infected and untreated 
positive control, infected and treated with: Kp-10 alone at 1 µM, kisspeptin antagonist p356 alone at 
1 µM, and combination treatments: Kp-10 (1 µM) + p356 (1 µM) and Kp-10 (1 nM) + p356 (1 µM). This 
was done to form the basis for the continuation of the present study. 
At processing of each time point, cell culture supernatants were harvested and subjected to expression 
analysis of selected cytokines. The cytokines chosen for expression analyses were: interferon (IFN)γ, 
interleukin-10 (IL-10), interleukin-17A (IL-17A), interleukin-1β (IL-1β), interleukin-1α (IL-1α), 
interlukein-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor (TNF)-α, 
macrophage inflammatory protein (MIP)-1α, MIP-1β and granulocyte macrophage colony stimulating 
factor (GM-CSF). These cytokines were chosen based on their immunomodulatory properties as 
described in Table 1.1. The expression levels of the secreted cytokines were determined employing 
Luminex multiplex assay. As a result of many proteins being expressed only in response to an 
inflammatory stimulus, all figures are displayed as percentage protein expression relative to the Mtb-
infected and untreated (positive control) samples (set to 100%).  
It must be noted that of the 5 patients recruited for this initial investigation, only data for 2 patients 
was viable, meaning that of the analytes analysed, 2 patients had responses that fell within the 
observable range of the assay i.e. the standard curve, deeming the data accurate for quantification. 
The responses/analyte readings for the remaining patients all fell below the observable range, 
meaning that the response/induction (concentration of analyte) was not sufficient to be measured.  Of 
the 12 analytes investigated using the luminex multiplex assay, only 5 analytes (GM-CSF, TNF-α, MIP-
1α, MIP-1β and IL-10) had responses that were within the range of the standard curve (Figure 






Figure 3.1: The effect of Kp-10 on Mycobacterium tuberculosis induction of tumour necrosis factor-α, 
macrophage inflammatory protein-1α and macrophage inflammatory protein-1β in PBMCs of non-pregnant 
healthy women. Cells were pre-incubated with treatment overnight and subjected to Mtb infection (MOI 5:1) 
for 2 hours the following day in the absence or presence of the respective treatments for the respective time 
points. Cell culture supernatants were harvested at 2 hours and subjected to luminex analysis. Percentage 
protein expression (± range) represented as a percentage relative to/plotted against the infected and untreated 
control (positive control) which was set to 100%. All graphs, where applicable, are representative of pooled 
data from 5 independent experiments whereby only 2 presented viable results. There were only sufficient 
responses for one patient (A388 from Table 3.1) for cytokines TNF-α and MIP-1β whereas for MIP-1α, two 
patients had sufficient responses hence the error bars within the graph. Statistical analysis could not be 





























Figure 3.2: The effect of Kp-10 on Mycobacterium tuberculosis induction of tumour necrosis factor-α, 
macrophage inflammatory protein-1α and macrophage inflammatory protein-1β in PBMCs of non-
pregnant healthy women. Cells were pre-incubated with treatment overnight and subjected to Mtb infection 
(MOI 5:1) for 2 hours the following day in the absence or presence of the respective treatments for the 
respective time points. Cell culture supernatants were harvested at 24 hours and subjected to luminex 
analysis. Percentage protein expression (± range) represented as a percentage relative to/plotted against the 
infected and untreated control (positive control) which was set to 100%. All graphs, where applicable, are 
representative of pooled data from 5 independent experiments whereby only 2 presented viable results. 
There were only sufficient responses for one patient (A388 from Table 3.1) for cytokines TNF-α and MIP-1β 
whereas for MIP-1α, two patients had sufficient responses hence the error bars within the graph. Statistical 


























Figure 3.3: The effect of Kp-10 on Mycobacterium tuberculosis induction of granulocyte macrophage colony 
stimulating factor and interleukin-10 in PBMCs of non-pregnant healthy women. Cells were pre-incubated with 
treatment overnight and subjected to Mtb infection (MOI 5:1) for 2 hours the following day in the absence or 
presence of the respective treatments for the respective time points. Cell culture supernatants were harvested 
at 24 hours and subjected to luminex analysis. Percentage protein expression (± range) represented as a 
percentage relative to/plotted against the infected and untreated control (positive control) which was set to 
100%. All graphs, where applicable, are representative of pooled data from 5 independent experiments whereby 
only 2 presented viable results. There were only sufficient responses for one patient (A388 from Table 3.1) for 

















At 2 hours post Mtb infection a 5 fold increase in TNF-α was observed (Figure 3.1A), there was a slight 
further induction of TNF-α in response to Kp-10 treatment (1 µM = 138.11% and 1 nM = 124.21%). It 
must be reiterated that due to the observation of effective responses in only 1-2 patient samples, it 
was not possible to do statistical analysis. The antagonist p356 had no effect on Mtb-induced cytokine 
expression for TNF-α (p356 alone at 1 µM = 113.39%). Treatment with Kp-10 (1 µM) + p356 (1 µM) led 
to an increased induction of TNF-α (148.75%) compared to the negligible increased induction for Kp-
10 (1 nM) + p356 (1 µM) (114.57%).  
Mtb infection led to a 2 fold induction of MIP-1α at 2 hours (Figure 3.1B) and treatment with Kp-10 
alone or together with p356 did not have an effect on the induction of MIP-1α, while treatment with 
p356 alone slightly reduced the induction level of MIP-1α (85.11% ± 8.19). The mean +/- range is 
indicative of the difference between the results from the results observed from the two patients. Mtb 
infection also led to a 2 fold induction of MIP-1β at 2 hours (Figure 3.1C). Treatment with Kp-10 or 
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p356 alone or together led to an increase in the induction of MIP-1β. Both concentrations of Kp-10 
showed similar responses (1 µM = 121.01% and 1 nM = 126.91%). The antagonist had no effect on 
MIP-1β induction (p356 alone = 104.49%), whereas Kp-10 together with p356 led to a slight increase 
in MIP-1β (Kp-10 (1 µM) + p356 (1 µM) (126.84%) and Kp-10 (1 nM) + p356 (1 µM) (114.81%). In 
general, overall treatment with Kp-10 (1 µM) + p356 (1 µM) led to a response greater then Kp-10 alone 
at both concentrations whereas treatment with Kp-10 (1 nM) + p356 (1 µM) led to a decreased 
response in induction when compared to Kp-10 at both concentrations. 
At 24 hours there was successful induction by Mtb for the cytokines presented. For TNF-α, at 24 hours 
post Mtb infection, a 10 fold increase was observed (Figure 3.2A). Slight inhibition of TNF-α induction 
was seen in response to Kp-10 treatment (1 µM = 70.50% and 1 nM = 84.92%). The antagonist, p356, 
had similar inhibitory effects to that of Kp-10 at 1 µM on Mtb-induced cytokine expression for TNF-α 
(p356 alone at 1 µM = 69.91%). Combination treatments such as Kp-10 (1 µM) + p356 (1 µM) led to 
slight inhibition of TNF-α expression (84.31%) as well as for Kp-10 (1 nM) + p356 (1 µM) (78.96%).  
For MIP-1α at 24 hours, Mtb infection again led to a 2 fold induction of MIP-1α (Figure 3.2B) and 
treatment with Kp-10 alone or together with p356 as well as p356 alone had varying effects on the 
induction of MIP-1α. Whilst both concentrations of Kp-10 showed inhibitory effects on MIP-1α 
induction, Kp-10 at 1 nM (52.05% ± 21.35) displayed greater inhibitory effects than Kp-10 at 1 µM 
(86.59% ± 22.32).Treatment with p356 showed a slight decrease in the induction level of MIP-1α 
(47.89% ± 21.31). Combination treatments displayed similar inhibitory effects to that of p356 showing 
that p356 enhanced its effects when combined with Kp-10. Both combination treatments were similar 
as Kp-10 (1 µM) + p356 (1 µM) (49.25% ± 20.87) was similar to Kp-10 (1 nM) + p356 (1 µM) (52.05% ± 
21.35). 
Mtb infection led to a 5 fold induction of MIP-1β at 24 hours (Figure 3.2C), treatment with Kp-10 or 
p356 alone or together led to a inhibitory effect of the induction of MIP-1β. The two concentrations of 
Kp-10 displayed a dose response effect in terms of inhibition of MIP-1β induction (1 µM = 60.77% and 
1 nM = 77.90%). The antagonist displayed slight inhibitory effcts on MIP-1β induction when alone 
(p356 alone = 65.74%) The antagonist slightly decreased the inhibitory effect of Kp-10 at 1 µM when 
in combination (Kp-10 at 1 µM + p356 at 1 µM = 69.64%) but had no effect when in combination with 
Kp-10 at 1 nM (Kp-10 at 1 nM + p356 1 µM = 78.60%). Both combination treatments displayed slight 
inhibitory effects on MIP-1β induction.  
With regards to GM-CSF at 24 hours, Mtb infection led to drastic 50 fold induction of GM-CSF (Figure 
3.3A). A slight inhibitory effect on GM-CSF induction was seen in response to Kp-10 treatment at 1 µM 
(62.32%), however Kp-10 at 1 nM had no effect (101.37%). Again the antagonist, p356, had similar 
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inhibitory effects to that of Kp-10 at 1 µM on Mtb-induced cytokine expression for GM-CSF (p356 alone 
at 1 µM = 57.25%). Combination treatments such as Kp-10 (1 µM) + p356 (1 µM) led to slight inhibition 
of GM-CSF expression (93.24%) as well as for Kp-10 (1 nM) + p356 (1 µM) (87.12%).  
For IL-10, Mtb infection led to a 2 fold induction at 24 hours (Figure 3.3B).  Treatment with Kp-10 or 
p356 alone or together led to an inhibition effect on the induction of IL-10. The two concentrations of 
Kp-10 displayed inhibitory effects of IL-10 induction similar to that of MIP-1β at 24 hours (1 µM = 
54.87% and 1 nM = 75.48%). The antagonist displayed inhibitory effects of IL-10 induction similar to 
Kp-10 at 1 µM when alone (p356 alone = 62.61%). The antagonist slightly decreased the inhibitory 
effect of Kp-10 at 1 µM when in combination (Kp-10 at 1 µM + p356 at 1 µM = 75.49%) and had slightly 
enhanced the inhibitory effect of Kp-10 at 1 nM when in combination with Kp-10 at 1 nM (Kp-10 at 1 
nM + p356 1 µM = 64.52%). 
For this timepeoint, treatment with Kp-10 (1 µM) + p356 (1 µM) led to a response greater then Kp-10 
alone at both concentrations with exception to MIP-1α (the response was less than both 
concentrations) and MIP-1β (the response was less than Kp-10 at 1 nM) (Figure 3.2B and Figure 3.2C). 
Treatment with Kp-10 (1 nM) + p356 (1 µM) led to a varied response in induction when compared to 
Kp-10 at both concentrations. Induction for combination treatments was lower than Kp-10 (1 nM) and 
higher than Kp-10 (1 µM) for TNF-α (Figure 3.2A) , lower than both Kp-10 (alone) concentrations for 
MIP-1α (Figure 3.2B) and higher than Kp-10 (1 µM) but the same for Kp-10 (1 nM) for MIP-1β (Figure 
3.2C). 
At 6 days post Mtb infection. No cytokines were measured as the response for all 5 patients was 
negligible and fell outside of the observable range (induction was too low to be quantified) and thus 
could not be accurately quantified for all analytes.  
In summary, Kp-10 treatment increases induction at 2 hours for TNF-α and MIP-1β whereas for MIP-
1α, Kp-10 treatment has little effect. At 24 hours, Kp-10 inhibited the Mtb-induction of TNF-α and MIP-
1β as well as the Mtb- induction of  IL-10 and GM-CSF. The antagonist p356 displayed partial agonistic 






3.1.2 Mtb infection and the culturing of PBMCs in AIM-V medium over a 
prolonged period of time caused a reduction in cell viability  
 
In order to establish the reason for a lack of response at the day 6 time point, the viability of the 
isolated PBMCs over the allotted time points i.e. 2 hours, 24 hours and 6 days, was investigated using 
a MTT colorimetric cell viability assay which was performed on the PBMCs of each patient. The assay 
is based on the reduction of yellow tetrazolium salt (MTT) to purple formazan crystals which are 
formed within the mitochondria of metabolically active cells, thus allowing for the determination of 
viable cells. Cell viability was determined as a percentage by measuring relative absorbance at 595 nm 
and plotting each treatment against the overall uninfected and untreated. The control for these tests 
was set as the untreated and uninfected control at 2 hours which was set to 100%. It must be noted 
that there was a decline in  absorbances measured for uninfected and untreated controls across the 
time points:  for 2 hours - 0,251, for 24 hours - 0,442 and for day 6 - 0,052. This gave further indication 
of a loss of cell viability. The MTT showed that from the 2 hour time point (Figure 3.4A) and the 24 
hour time point (Figure 3.4B), PBMCs remained viable (on average ±100% viability) whereby treatment 
and Mtb infection did not have a significant effect on cell viability. However, at day 6, there was a 
greater than 2 fold reduction in cell viability (Figure 3.4C) especially in the case of both Kp-10 







































Figure 3.4: Relative cell proliferation/viability of PBMCs over 2 hours, 24 hours and 144 hours with selected 
treatment. Whole blood was pre-incubated with treatment overnight and subjected to Mtb infection (MOI 
5:1) for 2 hours the following day in the absence or presence of the respective treatments for the respective 
time points (replenished each day). Supernatants were harvested at each time point (2, 24 and 144 hours) and 
the pellet was subjected to MTT treatment for 4 hours. Relative fold proliferation (±SEM) represented as a 
percentage relative to/plotted against the overall average uninfected and untreated control which was set to 
100. Graphs are representative of pooled data from 5 patient samples. One-way analysis of variance (ANOVA) 
followed by Dunn’s multiple comparison test were performed to compare the differences across all the 
treatments. Descriptive statistics was computed using the same software and p < 0.05 defines statistical 




3.1.3 Kisspeptin had an affect on Mtb infection based on Colony Forming Unit 
(CFU) count and Mtb uptake analysis 
 
CFU analysis was conducted on lysed PBMCs following the previously described PBMC infection assay. 
The analysis was performed on 9 patients in order to determine the effect of Kp-10 on Mtb 
uptake/infection.  
At processing of each time point, cell culture supernatants were removed. After the harvesting of 
supernatants the cell pellet was lysed and cells were plated in serial and sealed for incubation for four 
weeks. The number of viable bacteria was determined after four weeks, post incubation, and 
represented as CFU/ml. Mtb infection/uptake was analysed and statistical analysis was performed on 
each column. Unfortunately, for the 144 hour (day 6) time point, no infection/uptake was observed 
for all treatments and patient samples. 
 
The results from the CFU analysis (Figure 3.5) showed no significance difference between the 
treatments and the infected untreated control for both time points. The assay worked, as there was a 
significant difference between the untreated and uninfected control and the infected untreated 
control for both time points. 
 
For the 2 hour time point (Figure 3.5A), Kp-10 had a non-significant affect on the uptake of Mtb. Kp-
10 (1 nM) had the lowest CFU/ml count at 2 hours (2,5 X 104 CFU/ml ± 1,4 X 104 CFU/ml) when 
compared to the infected and untreated control (4, 38 X 104 CFU/ml ± 1,4 X 104 CFU/ml). The 
antagonist, p356, and Kp-10 at 1 µM had a similar affect on Mtb uptake when compared to the infected 
untreated control (p356 = 3, 40 X 104 CFU/ml ± 0,10 X 104 CFU/ml and Kp-10 = 3, 35 X 104 CFU/ml ± 
1,24 X 104 CFU/ml). The combination treatments enhanced the effect of the antagonist and Kp-10 
alone for both concentrations. Kp-10 (1 µM) + p356 (1 µM) was 3, 38 X 104 CFU/ml ± 0,56 X 104 CFU/ml 
and Kp-10 (1 nM) + p356 (1 µM) was 4, 53 X 104 CFU/ml ± 0,16 X 104 CFU/ml when compared to the 
infected and untreated control and the antagonist and Kp-10 alone.  
 
For the 24 hour time point (Figure 3.5B), Kp-10 again had a non-significant affect on the uptake of Mtb 
and the affects were similar to that at 2 hours. Kp-10 (1 nM) + p356 (1 µM) had the lowest CFU/ml 
count at 24 hours (1,6 X 103 CFU/ml ± 0,38 X 103 CFU/ml) when compared to the infected and untreated 
control (1, 98 X 103 CFU/ml ± 0,38 X 103 CFU/ml). The antagonist, p356, and combination treatment, 
Kp-10 (1 µM) + p356, had a similar affect on Mtb uptake when compared to the infected untreated 
control (p356 = 1,8 X 103 CFU/ml ± 0,18 X 103 CFU/ml and Kp-10 (1 µM) + p356 = 1, 74 X 103 CFU/ml ± 
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Figure 3.5: CFU/ml count after 4 weeks following infection and 2 hours and 24 hours incubation with selected 
treatment. Cells were pre-incubated with treatment overnight and subjected to Mtb infection (MOI 5:1) for 2 hours 
the following day in the absence or presence of the respective treatments for the respective time points (replenished 
each day). Supernatants were harvested at each time point (2 and 24 hours) and the pellet was subjected to lysing and 
plating on 7H11 agar plates (n= -1 to n = -4 dilution series) and left ot incubate for 4 weeks at 37 °C before counting. 
CFU/ml was plotted for each treatment with each column being compared to the  infected and untreated control 
(±SEM). Graphs are representative of pooled data from 9 patient samples. One-way analysis of variance (ANOVA) 
followed by Dunn’s multiple comparison test were performed to compare the differences across all the treatments. 
Descriptive statistics was computed using the same software and p < 0.05 defines statistical significance, where *, **, 
*** denotes p < 0.05; p < 0.001 and p < 0.0001 respectively. The symbol “ns” depicts no significance. 
 
0,24 X 103 CFU/ml). The combination treatments had opposite affects to the 2 hour timepoint as they 
decreased the effect of the antagonist and Kp-10 alone for both concentrations. Kp-10 (1 µM) + p356 
(1 µM) was 1, 74 X 103 CFU/ml ± 0,24 X 103 CFU/ml and Kp-10 (1 nM) + p356 (1 µM) was 1,6 X 103 
CFU/ml ± 0,38 X 103 CFU/ml when compared to the infected and untreated control and the antagonist 
and Kp-10 alone. Kp-10 alone increased Mtb uptake when compared to the combination treatments 
and the control. Kp-10 (1 µM) was 2, 23 X 103 CFU/ml ± 0,25 X 103 CFU/ml which was the greatest 
effect and Kp-10 (1 nM) which was 2, 03 X 103 CFU/ml ± 0,50 X 103 CFU/ml. 
 
Overall for both timepoints, The data was not significant with regards to statistical analysis and there 





















3.2 in vitro whole blood stimulation assay  
 
The initial experiments of this investigation described in section 3.1 involved infection with Mtb and 
working in a P3 facility, which is not without any risk and in general the assay was not suitable for the 
measurements required i.e. it was not sufficient in measuring appropriate cytokine induction in the 
majority of patients. Therefore, it was decided to establish an alternative model employing 
lipopoloysaccharides (LPS) and whole blood instead of Mtb and PBMCs. Initially, the LPS in vitro model 
system needed to be optimised. First optimising LPS stimulation time and optimal LPS concentration, 
thereafter, determining the pretreatment and posttreatment time with Kp-10 and p356. The blood 
was initially collected in K3 EDTA tubes and thereafter, in NaHep tubes. Based on the fact that p356 
displayed partial agonistic effects within the PBMC infection assay model, it was decided to exclude 
the antagonist from the whole blood stimulation assay and completely characterise the effects of Kp-
10. 
 
3.2.1 Establishing a whole blood in vitro immune response model using LPS 
 
Pathogen-associated molecular patterns (PAMPs) from foreign microorganisms are recognised by cells 
of the innate immune system. This recognition results in the stimulation of an immune response 
towards these PAMPs. A common PAMP includes LPS which is a bacterial endotoxin found within the 
outer membrane of gram-negative bacteria [135]. It is common to use LPS as a stimulating agent for 
cultured macrophages, PBMCs and whole blood, which are commonly used for in vitro assays in order 
to study immune responses [136,137,138,139]. The selected concentration of LPS depends on its 
biological origin, the cell line used, the stimulation time and the appropriate level of inflammatory 
response desired. It is known that cytokines, chemokines and inflammatory mediators present 
different expression patterns over time during the inflammatory response [140,141,142]. In this study 
we used LPS derived from the E. coli serotype 055: B5 (Cat. Number: L4005, Sigma-Aldrich/Merck). 
Concentrations of from 10 µg/ml to 1 ng/ml were tested. For these experiments, the negative control 
was cells not stimulated with LPS and not treated with Kp-10. Whereas the positive control was cells 






3.2.1.1. Optimising LPS stimulation time and LPS concentration range 
 
Whole blood taken from 4 healthy and non-pregnant women in EDTA tubes was sampled and 1 ml was 
placed into each tube for culture and LPS induction. Due to its inflammatory properties, high induction 
upon immune stimulation and time constraints, TNF-α was chosen as a readout for immune response 
to LPS to determine optimum experimental conditions. TNF-α was measured in harvested cell culture 
supernatants using sandwich ELISA after testing different LPS stimulation times (4 hours, 12 hours and 
24 hours) (Figure 3.6) at an LPS concentration of 10 µg/ml and 100 µg/ml. Figure 3.6A, shows that at 4 
hours after LPS stimulation a large induction was observed. This  induction was ± 2.5 fold greater for 
100 µg/ml LPS (784.65 pg/ml ± 24.01) than 10 µg/ml LPS (303.54 pg/ml ± 23.87). At 12 hours (Figure 
3.6B), induction was ± 4 fold greater for 100 µg/ml LPS (829.30 pg/ml ± 2.69) than 10 µg/ml LPS (212 
pg/ml ± 30.11). While, at 24 hours (Figure 3.6C), induction was ± 10 fold greater for 100 µg/ml LPS 
(788.70 pg/ml ± 12.13) when compared to 10 µg/ml LPS (75.61 pg/ml ± 15.98). The induction at 100 
µg/ml was consistent across all time points whereas the response to 10 µg/ml decreased at the 24 
hour timepoint. 
The 4 hour stimulation time (Figure 3.6A) proved sufficient for the experimental design, since, the 
maximal LPS induction of TNF-α was observed already at this time point for both LPS concentrations. 
The use of the 4 hour stimulation time point was also supported by literature [145,149,150] in order 





































3.2.1.2. Determining the optimal concentration of LPS 
 
Figure 3.6: Optimisation of stimulation time for a LPS-induced induction of TNF-α expression in whole blood. 
Whole blood was treated with 10 µg/ml or 100 µg/ml of LPS for 4 (A), 12 (B) and 24 (C) hours. Following 
stimulation,  supernatants were harvested and subjected to protein expression analysis by sandwich ELISA to 
detect TNF-α. Graphs displayed pooled data, representative of 4 independent samples for each stimulation time 
(±SEM). One-way analysis of variance (ANOVA) followed by Dunn’s multiple comparison test were performed to 
compare the differences across the different treatment groups. Descriptive statistics was computed using the 
same software and p < 0.05 defines statistical significance, where *, **, *** denotes p < 0.05; p < 0.001 and p < 
0.0001 respectively. The symbol “ns” depicts no significance. 
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In order test whether lower LPS concentrations will still direct an induction of TNF-α in whole blood  
the following LPS concentrations (1 µg/ml, 100 ng/ml and 10 ng/ml) were tested. It was decided to use 
the 4 hour and 6 hours stimulation times.   
Following 4 hours of LPS stimulation, TNF-α induction was clearly observed  for all concentrations of 
LPS. The results for TNF-α induction at 4 hours were as follows (Figure 3.7A): 1 µg/ml LPS = 1236 pg/ml 
± 49.13;  100 ng/ml LPS = 994.40 pg/ml ± 43.16 and 10 ng/ml LPS = 333.7 pg/ml ± 51.79 (less ± 4 fold 
than 1 µg/ml LPS and less ± 3 fold than 100 ng/ml LPS). The lowest induction was in response to 10 
ng/ml (± 5 fold less than the maximum at 1 µg/ml), the response 100 ng/ml was similar to the maximum 
induction and the maximum induction was in response to 1 µg/ml LPS. The 6 hour LPS stimulation time 
(Figure 3.7B) presented similar induction results, highlighting no significant difference between the 
two time points. The results for the 6 hour stimulation were as follows (Figure 3.7B): maximum 
induction at 1 µg/ml LPS = 1246 pg/ml ± 49.82; second highest induction at 100 ng/ml LPS = 1002 pg/ml 
± 55.60 and lowest induction at 10 ng/ml LPS = 321.60 pg/ml ± 51 (less ± 4 fold then 1 µg/ml LPS and 
less ± 3 fold then 100 ng/ml LPS).  
For subsequent experiments testing the effects of Kp-10 on LPS induced cytokine expression, it was 
decided to use 10 ng/ml at a 4 hour stimulation time as it proved sufficient in terms of TNF-α induction, 
since longer stimulation time did not further increase the induction and allowed for a shorter induction 
time and at a low LPS concentration. Since, pre-treatment/incubation with Kp-10 and/or p356 was 
required a few hours before LPS stimulation, this allowed maximal pre-incubation time since cell 




























3.2.1.3. Optimising the time for Kp-10 modulation of LPS-induced cytokine expression  
 
To optimise the Kp-10 pre-incubation time prior to LPS-induction of cytokine expression, whole blood 
was drawn from 5 healthy and non-pregnant women. Preliminary experiments were performed in 
order to determine the best time point to harvest cell culture supernatants for protein expression 
analysis of the selected cytokines. 
In order to measure Kp-10 effects on LPS-induced cytokine expression, it was decided to have a pre-
incubation time with Kp-10. Therefore, it was required to first optimise the pre-incubation time with 
Kp-10 prior to the 4 hour stimulation with LPS. Pre-incubation times 4 hours and 24 hours were tested 
initially to highlight a minimum and possible maximum range since a minimum time of preincubation 
with Kp-10 is required while a too long incubation may impact on the viability of the cells using a high 
concentration of Kp-10 (1 µM).  Following this, whole blood from healthy non-pregnant women was 
Figure 3.7: Optimisation of stimulation time and concentration for a LPS-induced induction of TNF-α 
expression in whole blood. Whole blood treated with tirations of LPS (1 µg/ml, 100 ng/ml and 10 ng/ml) for 4 
(A) and 6 hours (B). Cell culture supernatants were harvested and subjected to protein expression analysis. 
Graphs display pooled data, representative of 3 independent samples for each time point (±SEM). One-way 
analysis of variance (ANOVA) followed by Dunn’s multiple comparison test were performed to compare the  
difference between treatments. p < 0.05 defines statistical significance, where *, **, *** denotes p < 0.05; p < 




pre-incubated with a range of concentrations of Kp-10 (1 nM to 1 µM) treatment for 4 hours and 8 
hours.  
Following Kp-10 treatment, blood was then treated with 10 ng/ml of LPS for 4 hours. Cell culture 
Supernatants were collected following LPS stimulation. Figure 3.8 and Figure 3.9 show the protein 
expression profiles for TNF-α at these time points.   
Figure 3.8A shows TNF-α release from blood cells after 4 hours of pre-incubation with Kp-10 and 4 
hours of LPS stimulation. The results show that Kp-10 at 1 µM slightly inhibits 10 ng/ml LPS induction 
(From 588.10 pg/ml ± 37.48 for LPS alone to 491.50 ± 48.83 with Kp-10 at 1 µM). Kp-10 alone with no 
LPS stimulation had no effect on TNF-α induction (0 pg/ml) and was included as a control (Figure 3.8A). 
Pre-incubation with Kp-10 for 24 hours followed by a 4 hour LPS stimulation, did not show any 
induction for any of the treatments (Figure 3.8B).  
Since a pre-incubation for 24 hours did not show any LPS-induction it was decided to test an 
intermediate 8 hour pre-incubation time (Figure 3.9A). Cells were pre-incubated with Kp-10 treatment 
(Kp-10 titration: 1 µM – 1 nM) for 4 and 8 hours and stimulated with LPS at 10 ng/ml for 4 hours in the 
presence of fresh treatment. LPS alone induced expression of TNF-α for both pre-incubation times. . 
The peak in TNF-α protein expression was seen at 4 hours of pre-incubation (Figure 3.9A) whereby for, 
LPS (alone), induction was ± 2 fold higher (LPS at 10 ng/ml = 620.50 pg/ml ± 22.02)  than for the 8 hour 
pre-inubation time (LPS at 10 ng/ml = 298.30 pg/ml ± 6.012 ) (Figure 3.9B).  
For the 4 hour pre-incubation the results were varying at different concentrations of Kp-10: 1 µM = 
628.10 pg/ml ± 14.58 (slight induction); 10-7 M = 591.30 pg/ml ± 12.31 (slight inhibition); 10-8 M = 
645.90 pg/ml ± 52.44 (slight induction) and 1 nM = 591.80 pg/ml ± 76.12 (slight inhibition). Overall no 
concentration of Kp-10 had any significant effect on LPS-induced TNF-α expression. 
For the 8 hour pre-incubation time point, an indication of a dose-dependent Kp-10 inhibitory effect 
was seen up until Kp-10 at 1 nM and was observed as follows for the various Kp-10 concentrations:  1 
µM = 242.60 pg/ml ± 16.46 (slight inhibition); 10-7 M = 226.40 pg/ml ± 34.47 (slight inhibition); 10-8 M 
= 220.10 pg/ml ± 16.21 (slight inhibition) and 1 nM = 269.20 pg/ml ± 76.74 (slight inhibition) (Figure 
3.9B). As a control, Kp-10 alone at different concentrations did not induce TNF-α expression, therefore 
Kp-10 as a control was excluded from further investigations as it did not play a role in cytokine 
induction alone. Kp-10 displayed similar effects for both incubation times however the effect was more 
pronounced for the 8 hour pre-incubation time (Figure 3.9B). Overall, Kp-10 attenuates the LPS 
response but a significant dose-dependent effect is not seen.  
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Figure 3.8: Optimisation of stimulation time and concentration for a LPS-induced induction of TNF-α 
expression in whole blood. Whole Blood was pre-treated for 4 and 24 hours with Kp-10 (1 µM) followed by a 
treatment with LPS (10 ng/ml) for 4 hours. Stimulation was done in the presence of replenished Kp-10 treatment 
for respective samples Cell culture Supernatants were harvested and subjected to protein expression analysis 
via sandwich ELISA to detect TNF-α. Graphs display pooled data, representative of 3 independent samples for 
each time point (±SEM). One-way analysis of variance (ANOVA) followed by Dunn’s multiple comparison test 
were performed to compare the difference between treatments. p < 0.05 defines statistical significance, where 
*, **, *** denotes p < 0.05; p < 0.001 and p < 0.0001 respectively. The symbol “ns” depicts no significance. 
 
In summary, Kp-10 had a greater inhibitory effect on LPS-induced expression of TNF-α following 8 hour 
pre-incubation than compared to 4 hour pre-incubation time. A suggestive (non-significant) dose 
response was also observed for the 8 hour pre-incubation with Kp-10 time point, whereas for the 4 
hour pre-incubation time point, no significant effects were observed. 
As we wanted to assess the effects of kisspeptin treatment on LPS-induced expression of multiple 
cytokines, chemokines and inflammatory mediators, the time point for sampling protein expression 
levels was chosen to best represent the peaks in expression of the cytokines under investigation in this 
experiment and from what was seen in literature [143]. In addition, the time point was based on the 
results of the optimisation as the 8 hour pre-incubation paired with a 4 hour LPS stimulation provided 
the longest possible pre-incubation with Kp-10 while still ensuring TNF-α (cytokine) induction. 
Therefore, it was decided that the 8 hour pre-incubation plus the 4 hour LPS stimulation proved 
optimum for the in vitro inflammatory model and this workflow is summarised in Figure 3.10. The 


































3.2.2 Determination of the effect of Kp-10 on IL-1β, IL-10, TNF-α and IL-6 
expression in the whole blood of non-pregnant and healthy women using an in 
vitro infection model  
 
The workflow for the established in vitro inflammatory model that generated the results seen under 
this section is summarised in Figure 3.10. Whole blood was taken from 5 healthy and non-pregnant 





Figure 3.9: Optimisation of stimulation time and concentration for a LPS-induced induction of TNF-α 
expression in whole blood. Whole blood was pre-treated for 4, 6 (data not shown due to unsuccessful LPS-
induction) and 8 hours with Kp-10 (1µM [-6] to 1 nM [-9]) followed by a treated with LPS (10 ng/ml) for 4 hours. 
Stimulation was done in the presence of replenished Kp-10 treatment for respective samples. Cell culture 
Supernatants were harvested and subjected to protein expression analysis via sandwich ELISA to detect TNF-α 
expression. Graphs display pooled data, representative of 2 independent samples for each time point (±SEM). 
One-way analysis of variance (ANOVA) followed by Dunn’s multiple comparison test were performed to 
compare the difference between treatments. p < 0.05 defines statistical significance, where *, **, *** denotes 












LPS induced (10 ng/ml) induced TNF-α expression of 233.00 pg/ml ± 68.93 pg/ml (Figure 3.11A). Kp-10 
inhibited TNF-α for all concentrations (1 µM – 1 pM) especially at the lower concentrations (10-10 M to 
1 pM) when compared to the control and were as follows: 10-10 M (84.93 pg/ml ± 3.17) (± 3 fold 
inhibition); 10-11 M (87.42 pg/ml ± 0.54) (± 3 fold inhibition) and 1 pM (119.80 pg/ml ± 15.62) (± 2 fold 
inhibition). The inhibition was varied across the different concentrations with 10-10 M, showing the 
greatest inhibition (Figure 3.11A). The rest of the concentrations for Kp-10 only showed slight 
inhibition and results for the remaining concentrations were as follows: 1 µM (178.50 pg/ml ± 58.06); 
10-7 M (220.30 pg/ml ± 78.18) (negligible inhibition); 10-8 M (199.00 pg/ml ± 63.76); 1 nM (191.30 pg/ml 
± 67.66).  
Due to the very little LPS-induction oF IL-1β (10.16 pg/ml ± 5.44) (Figure 3.11B) not much can be 
observed from the data except that Kp-10 has a negligible effect on IL-1β expression despite the outlier 
seen at Kp-10 (1 pM) of 58.84 pg/ml ± 21.38.  
LPS at 10 ng/ml resulted in a marked induction of IL-6 (420.10 pg/ml ± 15.02). Kp-10 had a small 
inhibitory effect on LPS-induced expression of IL-6 (23% reduction) (Figure 3.11C)  at a concentration 
10-10 M (323.0 pg/ml ± 54.48), while other Kp-10 concentraations did not affect the level of LPS-induced 
IL-6 expression.  
Reviewing the effect of Kp-10 on IL-10 expression (Figure 3.11D), since, there was no induction by LPS 
it was not possible to examine the effect of Kp-10 on LPS induction of IL-10 expression. In summary, 
Kp-10 elicited more of a response at lower concentrations especially 10-10 M with the exception of IL-





seed in tubes 







Add 10 ng/ml 






Spin down cells 






Figure 3.10: Diagram summarising the work flow for the established in vitro inflammatory model using 



























Figure 3.11: Effect of Kp-10 on selected cytokines on protein expression following a LPS-induced inflammatory 
response. Whole blood was treated with 10 ng/ml of LPS for 4 hours following a 8 hour pre-incubation with 
treatment (Kp-10 1µM [-6] to 1 pM [-12]). Stimulation was done in the presence of fresh treatment. Cell culture 
Supernatants were harvested and subjected to protein expression analysis via sandwich ELISA to detect TNF-α 
expression. Graphs display pooled data, representative of 4 independent samples (±SEM). IL-10 had no response 
detected. One-way analysis of variance (ANOVA) followed by Dunn’s multiple comparison test were performed 
to compare the difference between treatments. p < 0.05 defines statistical significance, where *, **, *** 




3.2.3 Comparison of EDTA and Sodium Heparin (NaHep) blood collection tubes 
for assay design 
 
Previously, using a 8 hour pre-incubation time did not yield significant data. It was decided that one 
may achieve a greater response utilising a longer pre-incubation time with Kp-10. Since there was no 
response/induction at 24 hours for whole blood collected in K3 EDTA tubes (Figure 3.8B), it was 
decided to use NaHep tubes as an alternative based on the results of previous studies, reporting a 
better use for cytokine expression analysis [144]. Following the usual model set-up as described in 
Figure 3.10, observations illustrated that all concentrations of Kp-10 had no effect on TNF-α production 
(Figure 3.12) although induction at 10 ng/ml was much higher (± 4 fold) at 1007 pg/ml ± 3.13 (Figure 
3.12) compared to at 10 ng/ml 233.00 pg/ml ± 68.90 for blood collected in EDTA tubes (Figure 3.11A). 
The effect of Kp-10 at varying concentrations on TNF-α induction remained consistent throughout 
(ranged from lowest being Kp-10 at 1 nM = 971 pg/ml ± 13.80 to the highest being Kp-10 at 10-7 M = 
990.60 ± 7.70) and in general Kp-10 had no effect on TNF-α induction.  It was observed that cells did 
respond after 24 hour pre-incubation (LPS 10 ng/ml = 866.10 pg/ml ± 114.30) (Figure 3.13) unlike 
previous experiments whereby cells would not respond after 24 hours of pre-incubation and then 







































Figure 3.12: Effect of Kp-10 on TNF-α protein expression following a LPS-induced inflammatory response using NaHep blood 
collection tubes. Whole blood was treated with 10 ng/ml of LPS for 4 hours following a 8 hour pre-incubation with treatment (Kp-
10 1µM [-6] to 1 pM [-12]). Stimulation was done in the presence of fresh treatment. Cell culture Supernatants were harvested 
and subjected to protein expression analysis via sandwich ELISA to detect TNF-α expression. Graphs display pooled data, 
representative of 4 independent samples for TNF-α (±SEM). One-way analysis of variance (ANOVA) followed by Dunn’s multiple 
comparison test were performed to compare the difference between treatments. p < 0.05 defines statistical significance, where 
*, **, *** denotes p < 0.05; p < 0.001 and p < 0.0001 respectively. The symbol “ns” depicts no significance. 
 
Figure 3.13: Effect of Kp-10 on TNF-α protein expression following a LPS-induced inflammatory response using NaHep blood 
collection tubes. Whole blood was treated with 10 ng/ml of LPS for 4 hours following 24 hours of incubation without treatment. 
Cell culture Supernatants were harvested and subjected to protein expression analysis via sandwich ELISA to detect TNF-α 
expression. Graphs display pooled data, representative of 3 independent samples for TNF-α (±SEM). One-way analysis of variance 
(ANOVA) followed by Dunn’s multiple comparison test were performed to compare the difference between treatments. p < 0.05 




Due to the lack of Kp-10 induced effects at a pre-incubation time of 8 hours with 4 hours of LPS 
stimulation using NaHep blood collection tubes, paired with the ability to culture whole blood for a 
longer time point, it was decided to test the effects of Kp-10 usingr a longer pre-incubation time. We 
thus treated whole blood for 24 hours, 48 hours and 72 hours (Figure 3.14, Figure 3.15 and Figure 3.16) 
prior to being stimulated with LPS at 10 ng/ml in the presence of treatment for 4 hours, replenishing 
the Kp treatment every 24 hours for the 48 and 72 hour time points. It must be noted that only two 
Kp-10 concentrations (1 µM and 10 -8 M) based on performance in previous experiments) could be 
tested at 48 hours (Figure 3.15) due to reagent and patient recruitment (sample) limitations 
When testing the effect of Kp-10 on LPS -induced IL-6, IL-1β, IL-10 and TNF-α expression (Figure 3.14, 
Figure 3.15 and Figure 3.16) over 24, 48 and 72 hours, the following  effects were seen: 
For TNF-α LPS-induced expression at 24 hours (Figure 3.14A), the results remained fairly consistent as 
to what was seen in Figure 3.12. At 24 hours LPS induction at 10 ng/ml for TNF-α expression was 
relatively the same as those samples treated with Kp-10 at all concentrations (24 hours = 1006 pg/ml 
± 3.36). For IL-6, at 24 hours (Figure 3.14B), LPS at 10 ng/ml induced IL-6 expression (792.0 pg/ml ± 
0.90). Only a slight inhibitory effect was seen by Kp-10 and that was at 10-7 M (757.50 pg/ml ± 34.24). 
















Figure 3.14: Effect of Kp-10 on selected cytokines on protein expression following a LPS-induced inflammatory 
response using NaHep blood collection tubes. Whole blood was treated with 10 ng/ml and 1 µg/ml of LPS for 4 
hours following a 24, 48 and 72 hour pre-incubation with treatment (Kp-10 1µM [-6] to 1 nM [-9] and 1 µM + 10-
8 M for 48 hours). Treatments were replenished every day and Stimulation was done in the presence of fresh 
treatment. Cell culture Supernatants were harvested and subjected to protein expression analysis via sandwich 
ELISA to detect TNF-α expression. Graphs display pooled data, representative of 2 independent samples for the 






























A varied display of results was observed for IL-1β (Figure 3.14C). At 24 hours, LPS at 10 ng/ml induced 
expression of IL-1β (612.30 pg/ml ± 113.2). This induction was inhibited by Kp-10 at all concentrations 
with Kp-10 at 10-7 M (246.50 pg/ml ± 75.97 (± 3 fold less)) having the greatest inhibitory effect and 1 
µM being the least effective at 528.30 pg/ml ± 38.74 (slight inhibition) which proved to be unexpected. 
The remaining two concentrations inhibited LPS-induced expression in a similar manner to that of Kp-
10 at 10-7 M (10-8 M = 322.90 pg/ml ± 54.49 and 1 nM = 280.80 pg/ml ± 53.04). For IL-10 (Figure 3.14D) 
no effect from Kp-10 was seen and once again, as previously seen,  there was no induction by LPS at 
10 ng/ml at 24 hours.   
At 48 hours LPS induced TNF-α expression at 10 ng/ml for (1014 pg/ml ± 0.43) (Figure 3.15A). An 
inhibitory effect of Kp-10 on TNF-α induced expression was only seen at 48 hours for 10-8- M (755.8 
pg/ml ± 253.60) (Figure 3.15A). The remaining effects were consistent with that seen for normal LPS-
induction at 10 ng/ml.  At 48 hours LPS at 10 ng/ml induced a response in IL-6 induction (784.10 pg/ml 
± 1.07) (Figure 3.15B).  An inhibitory effect was seen for Kp-10 at 10-8 M (10-8 M = 580.70 pg/ml ± 
192.60), however due to the spread in error range, this can be ruled out and declared negligible.  At 
48 hours for IL-1β  (Figure 3.15C), Kp-10 only inhibited LPS induction at a concentration of 10-8 M (from 
LPS 10 ng/ml = 50.60 pg/ml ± 14.05 to 10-8 M = 32.23 pg/ml ± 6.34). There was induction by 10 ng/ml 
LPS for IL-10 at 48 hours of 133.60 pg/ml ± 49.65 (Figure 3.15D). Kp-10 inhibited the effects of LPS-
induced IL-10 expression, having a greater effect at a concentration of 10-8 M (1 µM = 88.34 pg/ml ± 














Figure 3.15: Effect of Kp-10 on selected cytokines on protein expression following a LPS-induced inflammatory 
response using NaHep blood collection tubes. Whole blood was treated with 10 ng/ml and 1 µg/ml of LPS for 4 
hours following a 24, 48 and 72 hour pre-incubation with treatment (Kp-10 1µM [-6] to 1 nM [-9] and 1 µM + 10-
8 M for 48 hours). Treatments were replenished every day and stimulation was done in the presence of fresh 
treatment. Cell culture Supernatants were harvested and subjected to protein expression analysis via sandwich 
ELISA to detect TNF-α expression. Graphs display pooled data, representative of 2 independent samples for the 































For TNF-α at 72 hours there was successful induction for LPS alone which was 999.90 pg/ml ± 10.85 
(Figure 3.16A). Kp-10, at all concentrations, had no effect on TNF-α induction at 72 hours. For IL-6 at 
72 hours (Figure 3.16B), slight inhibition was seen at Kp-10 = 10-7 M (487.50 pg/ml ± 24.34) when 
compared to  LPS alone at 10 ng/ml (612.10 pg/ml ± 160.0). The rest of the Kp-10 concentrations 
displayed no effect on IL-6 induction at 72 hours. The error range for LPS alone is wide, therefore 
although we do see inhibition at 10-7M this is not significant. For IL-1β at 72 hours (Figure 3.16C) no 
effects were seen besides an enhancement of induction at Kp-10 10-8 M (from 1.32 pg/ml ± 0.72 for 
LPS alone to 4.13 pg/ml ± 1.19). In general induction at 72 hours was negligible, so the results cannot 
be deemed conclusive in any way. For IL-10 at 72 hours there was induction by LPS of 3.99 pg/ml ± 
3.10   (Figure 3.16D).  Kp-10 enhanced IL-10 expression at all concentrations except for 1 µM Kp-10 
which showed inhibition (0.30 pg/ml ± 0.30). Again the greatest effect was shown at 10-8 M 
(13.42pg/ml ± 3.33). The other two concentrations displayed similar enhancement of IL-10 expression: 
























Figure 3.16: Effect of Kp-10 on selected cytokines on protein expression following a LPS-induced inflammatory 
response using NaHep blood collection tubes. Whole blood was treated with 10 ng/ml and 1 µg/ml of LPS 4 
hours following a 24, 48 and 72 hour pre-incubation with treatment (Kp-10 1µM [-6] to 1 nM [-9] and 1 µM + 10-
8 M for 48 hours). Treatments were replenished every day and Stimulation was done in the presence of fresh 
treatment. Cell culture Supernatants were harvested and subjected to protein expression analysis via sandwich 
ELISA to detect TNF-α expression. Graphs display pooled data, representative of 2 independent samples for the 









Chapter 4  Discussion 
 
Successful pregnancy is dependent on the development of physiological immune tolerance of the 
maternal immune system towards the genetically foreign fetus. It is known that the mother’s body 
undergoes significant changes during pregnancy whereby hormonal regulation within the periphery 
and within circulation dictates, with specific reference to immune reactivity and metabolism, these 
changes [7]. Hormones therefore are important regulators of the functional activity of the immune 
system and immune cells comprising this system [5,6,7]. At the site of placentation, hormones are 
secreted by the placenta which, in part, function to protect the fetus from the aggressive immune 
response of the mother [16]. Previously, kisspeptin has been positively implicated in regulating the 
functional activity of immune cells [7].  
Development of maternal immune tolerance towards the genetically foreign fetus is dependent on the 
several factors, of which the most important factors include the interactions between a range of 
cytokines secreted at the site of implantation by maternal and fetal cells in addition to a shift in the 
ratios of Th1/Th2 cytokine subsets [10]. Gestational hormones and stimulation of trophoblast cells is 
essential for the development of the decidua from the endometrium. This development is dependent 
on the communication between the developed decidua and trophoblast cells which is mediated by 
cytokines and cell surface receptors [10,104]. In addition to placentation, cellular immunity is mediated 
by specific effector cells as well as the cytokines they produce. It has been shown that the effects of 
cell-mediated immunity have deleterious consequences on the fetus during pregnancy.  
The two functional subsets of Th cells responsible for inducing different effector responses include: 
Th1 cells which induce several responses including cell-mediated cytotoxic and inflammatory reactions 
through the release of IFN-γ, TNF-α and IL-2 [8,17,18] and contrasting to this, Th2 cells, which have 
been associated with full term and successful pregnancy, enhance the production of B cell antibodies 
through the release of cytokines: IL-4, IL-5, IL-6 and IL-10 [17,18]. Maintaining certain levels of 
cytokines and chemokines is imperative for the regulation of the immune system during pregnancy. 
More so, maintenance of an appropriate cytokine balance at the maternal–fetal interface and in 
circulation is crucial for successful pregnancy.  
The effects of kisspeptin have been studied on the cytokines IL-10 and IL-17A as well as aTreg and Th17 
cells, which have been shown to be significant role players in the immune response during pregnancy 
[5,7]. The experiments done for this study were established to investigate the effects of kisspeptin on 
all cytokines (pro- and anti-inflammatory) which, based on the results, may elucidate certain 
mechanisms which are implicated in the determination of pregnancy outcome. In this study we tried 
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to establish the role of kisspeptin in regulating cytokine and chemokine expression, which would 
provide further elucidation into how the hormone plays a role in facilitating placentation and 
ultimately full term pregnancy.   
 
4.1 Establishment of the immunomodulatory effects of kisspeptin 
using an in vitro PBMC infection assay  
In this study, we used a previously established in vitro PBMC infection assay model to determine the 
immunomodulatory effects of kisspeptin treatment on Mycobacterium tuberculosis (Mtb) induced 
immune response in PBMCs. The experimental work conducted in this thesis is a pilot study, aiming to 
establish a foundation i.e. an in vitro proof-of-concept required for further investigation and 
experimentation. The PBMC infection model was not adequate to establish the effect of Kp-10 on Mtb-
induced cytokine expression. 
 
4.2 Investigating the role of kisspeptin in regulating the induction of 
cytokines  
In this investigation the pro-inflammatory cytokines IFN-γ, IL-17A, IL-1β, IL-1α, IL-6, TNF-α, and GM-
CSF , chemokines MCP-1, MIP-1α and MIP-1β, and anti-inflammatory cytokine IL-10 were selected for 
protein expression analysis. The chemokines and pro-inflammatory cytokines have previously been 
shown to be upregulated during infection whilst IL-10 can function as either an anti-inflammatory or 
immunosuppressive cytokine during infection [141,142]. Literature highlights that IL-1β is the most 
stable (longest half life)cytokine followed by IFN-α, IL-1α, IFN-γ, IL-6, and TNF-α [27,31] which is 
important to note in the context of this study.  A Luminex multiplex assay was conducted in order to 
assay multiple cytokines at once and gain a broader determination of the immunomodulatory effects 
of kisspeptin on cytokine expression when stimulated with a pathogen. It must be noted that the data 
presented was limited in terms of patient number. 5 patients were used in the study investigating Mtb-
induced cytokine repsponses in PBMCs, in order to outline the effects of kisspeptin on cytokine 
expression. The initial study was low-powered with the goal of establishing the hypothesis presented 
in this study and therefore justifying future investigations and experimentation. Of the 5 patients 
recruited for this initial investigation, only data for 2 patients was viable, meaning that of the analytes 
analysed, 2 patients had responses that fell within the observable range of the assay i.e. the standard 
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curve, deeming the data accurate for quantification. For the remaining 3 patients there was insufficient 
induction by Mtb and the readings all fell below the observable range therefore the repsonse was not 
sufficient in order to be measured.  Of the 12 analytes investigated using the luminex multiplex assay, 
only 5 analytes (GM-CSF, TNF-α, MIP-1α, MIP-1β and IL-10) had responses that were within the 
observable range of the standard curve (Figure 3.1, Figure 3.2 and Figure 3.3). Therefore, data from 
the initial experiments were suggestive and not reliable based on the number of repeats included in 
the analysis. Statistics could not be conducted on luminex data based on the fact that only 2 out of the 
5 patient samples produced observable/viable data, therefore the data collect is only suggestive of a 
pattern and more samples would be needed to make more accurate conclusions.   
Major findings from the protein expression analysis of this initial investigation include the effect of 
kisspeptin-10 on pathogen (Mtb) induced pro- and anti- inflammatory cytokine and chemokine 
expression. In addition, the efficiency of AIM-V medium in conjunction with prolonged Mtb exposure 
for the culturing PBMCs over a certain duration was investigated.  
At the 2 hour time point, cytokine responses were induced and measured for MIP-1α, MIP-1β and TNF-
α (Figure 3.1, Figure 3.2 and Figure 3.3). However, in general, Kp-10 at both concentrations (1 µM and 
10 nM) had no effect on cytokine expression for TNF-α, MIP-1β and MIP-1α at 2 hours. Protein 
expression analysis data showed, in general, inhibition of MIP-1α, MIP-1β, TNF-α, IL-10 and GM-CSF 
by Kp-10 relative to the control (100%) following 24 hours. Following analysis of Figures 3.1, Figure 3.2 
and Figure 3.,3, it was expected to see the inhibition of pro-inflammatory cytokines, however the 
inhibition of IL-10 was not expected, as literature has shown kisspeptin to have the opposite effect on 
IL-10 i.e. induction of anti-inflammatory immunosuppressive properties and thus induction of IL-10 
expression [5,16]. It has been shown that elevated IL-4 and IL-10 and reduced IL-2 and IFN-γ production 
by peripheral blood mononuclear cells (PBMCs) are associated with successful pregnancy outcomes 
[37,141]. Unfortunately, based on the fact that an inhibition of IL-10 by Kp-10 was observed as well as 
the inhibition of pro-inflammatory cytokines, it is difficult to correlate Kp-10-mediated effects with 
literature which suggests the inhibition of pro-inflammatory cytokines and induction of anti-
inflammatory cytokines being associated with successful pregnancy outcomes.  However, the 
inhibition of MIP-1α, MIP-1β and TNFα and GM-CSF by Kp-10 may suggest  a potential inhibitory role 
of Kp-10 of Th1 type/pro-inflammatory cytokines and chemokines whereby the suppression of Th1 
type cytokines has been associated with fetal uptake and successful pregnancy outcomes [17]. No 
accurate statement can be made based on the large inter-patient variability within the results, lack of 
statistical analysis due to low samples size and in general low sample size. The differences between 
the findings of this study and others, like that of Gorbunova, et al. and Shirshev, et al., may be 
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attributed to the same reason, as these other studies had larger patient cohort/sample size  and 
therefore could infer more from their data. 
For the kisspeptin antagonist, p356, a suggestive partial agonistic effect was observed when used alone 
and in combination with Kp-10 (Figure 3.1 , Figure 3.2 and Figure 3.3). This effect has been previously 
supported by an investigation using the blood of canines in literature [145]. This finding suggests that 
p356 may act as an agonist depending on the induction/stimulation model used in conjunction with 
the kisspeptin-induced system measured. The observed unexpected inhibitory effect of p356 
(kisspeptin antagonist) on cytokine responses, which was similar to the effect of Kp-10, indicates that 
p356 in this signalling system has  partial agonistic activity. Therefore, in agreement with literature, a 
synthetic ligand that is an antagonist in one signalling system may be found to be agonistic in a 
different signalling system [145].   In future, it would be better to use other known kisspeptin 
antagonists (p234, p271, p354) [145], which may elicit improved responses and further validate that 
the effects seen are specifically via the kisspeptin receptor GPR54.  
Although there was successful induction for certain cytokines and chemokines by Mtb for the 2 hour 
and 24 hour timepoint, at the day 6 time point no cytokines were measured and the response for all 5 
patients was negligible and fell outside of the observable range thus could not be accurately quantified 
for all analytes.  In order to establish why there was no response at the day 6 time point, the viability 
of the isolated PBMCs over the allotted time points i.e. 2 hours, 24 hours and day 6, was investigated 
(Figure 3.4). Uninfected cells had a decrease in viability at day 6 based on a reduction in absorbance 
readings  (2 hours (0,251), day 1 (0,442) and day 6 (0,052)).A possible explanation for this could be that 
the use of AIM-V was not sufficient for culturing PBMCs up to a day 6 time point. In addition, cell 
viability for infected samples and samples with treatment saw a reduction of greater then 50% in cell 
viability at day 6 when compared to both 2 hours and 24 hours. A reason for this reduction could be 
that the MOI was possibly too high and therefore prolonged Mtb infection over 6 days may have 
caused cell death which would have had an impact on cell viability. A possible suggestion to alleviate 
this problem would be to either lower the MOI, increase cell seeding number or do an experiment over 
lesser duration of time.  
For future work, making use of Mtb infection at a lower and more appropriate MOI could yield more 
consistent results. The extreme exposure of PBMCs to Mtb infection could have resulted in cell death 
therefore leading to an response reduction in cell viability over 6 days. Mtb infection of PBMCs 
(macrophages included), is representative of acute immune response and not necessarily chronic 
inflammation which may be a more consistent and representative obstacle to overcome during the 
early stages of pregnancy. In this study only the acute immune response was tested. Increasing cell 
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number when seeding could yield cytokine responses sufficient enough to be quantified via Luminex 
as the amount of cells expression cytokines would be greater and this would lead to a more 
concentrated cytokine response. It was concluded, from the data, that PBMCs could not be cultured 
for the duration of a full experiment as less than 50% of total cells were viable by day 6 (Figure 3.4C) 
when compared to 2 hours and 24 hours. 
Further optimisation of the existing in vitro infection model needs to be done whereby a titration of 
kisspeptin could be included along with an MTT analysis as to establish the relative IC50 of the hormone 
and completely characterise the hormone. However, the major setback of this model system would be 
that the requirements for experimentation proved to arduous and the use of Mtb in the biosafety level 
3 was deemed inefficient and uneccessary for what was being tested. It was thus better to move to an 
alternative model system.  Based on the demands and limitations of the assay, it was decided to move 
on to a more established means of inflammatory stimulation using LPS. LPS is a more controlled means 
of stimulation based on the ability to use set concentrations which may be deemed more consistent 
than using Mtb. However, LPS is still only representative of acute inflammation. An improvement and 
possible extension in order to investigate modulation of a chronic response, especially when this might 
be better in representing the physiology of pregnancy, would be to conduct stimulation/infection 
assays using pregnant mice models over a gestational period. In addition, it was intended that through 
the use of a time course in the stimulation assays, chronic inflammation could be replicated, however 
this did not prove to be completely successful.  
Immune response is the product of multiple events and relies on several avenues of communication 
between many different cell types (specialised adaptive immune cells, fibroblasts, epithelial cells and 
specialised innate immune cells) within their environment [88,142,143]. The use of PBMCs, although 
beneficial for culturing and well established for protein expression analysis, makes use of monoculture 
taken out of the usual context of the tissue microenvironment.  This justified an additional need for an 
alternative, and that was making use of whole blood. In saying this, although the PBMC infection model 
was previously established and tested, further optimisations need to be done to ensure that it is robust 
and that the results obtained are reproducible.  In addition, the concentrations of kisspeptin used in 
this model were not biologically relevant to in vivo experiments where the concentrations of kisspeptin 
ranged from 4.60 pmol/L to 9.60 pmol/L [5,6,16].  
In summary, the findings from this investigation were suggestive and non-significant, and kisspeptin 






4.2.1 Kisspeptin showed little to no effect on Mtb uptake/infection 
 
It was important to investigate the effect of Kp-10 on Mtb uptake in order to understand whether cells 
displayed different cytokine responses based on the severity of Mtb uptake/infection. Overall the 
results from the CFU analysis (Figure 3.5) showed no significance difference between the treatments 
and the infected untreated control for both time points i.e. at 2 hours and 24 hours. Therefore, Kp-10 
had no effect on Mtb uptake so the state of infection was relatively consistent throughout all samples 
meaning that this would have no effect on cytokine expression. Due to the large inter-patient 
variability and low sample size, it is difficult to affirm anything except that Mtb uptake was not effected 
by Kp-10 and p356 treatment.  
 
4.3 Establishing a  in vitro whole blood immune response model 
For this section of the study, an in vitro immune response model was established in order to 
determine the effects of Kp-10 on LPS-induced cytokine expression using whole blood. It was decided 
to use a model that does not involve a pathogen-induced means of inducing cytokines nor would it 
require the use of the P3 faclitity. In addition, the use of PBMCs requires a large quantity of blood from 
patients thus it was decided to move to the use of whole blood which requires less blood and which 
would also beneificial for future work when testing pregnant women. Due to ethical limitations, one 
cannot take a large quantity of blood from patients, especially in the case of pregnant women (future 
studies), as not to effect a patient’s health and well-being. Whole blood, based on previous studies, 
proves to be more physiologically relevant than PBMCs and therefore would be a better representation 
of kisspeptin effects in response to inflammation based on the fact that the immune response is the 
product of multiple events and relies on several avenues of communication between many different 
cell types (specialised adaptive immune cells, fibroblasts, epithelial cells and specialised innate 
immune cells) [143,146]. It is thus preferred to make use of whole blood for studying cytokine and 
chemokine induction by LPS as it allows optimal preservation of the physiological milieu in which cell 
activation is as a results of the interaction between LPS and plasma molecules [143,146]. In addition, 
there was a greater response to kisspeptin treatment when using LPS as a stimulating agent as opposed 
to the previously used Mtb.   
Based off preliminary tests using varying concentrations of LPS at 4, 6, 12 and 24 stimulation time, 4 
hours of stimulation was concluded to be the optimum time point for LPS stimulation. Following this, 
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the optimum pre-incubation time point with kisspeptin was tested. Literature suggests that 72 hours 
is optimum for kisspeptin reactivity using a LPS stimulation assay of monocytes [5], however using K3 
Ethylenediaminetetraacetic acid (EDTA) tubes for blood collection did not allow for cell culturing up to 
24 hours prior to LPS stimulation. The cytokines present within the supernatant are a product of the 
initial stimulation as TNF-α is expressed early upon infection [136], however cytokines may also 
degrade over time which may be a reason as to why there was no response following 24 hours.  As 
expected, the peak in TNF-α protein expression was seen at a shorter pre-incubation time with Kp-10 
(4 hours) followed by a 4 hour LPS stimulation. This may be explained by optimum cell viability and/or 
initial immune response and accumulation of cytokine at this timepoint which can be further validated 
by the complete lack of TNF-α expression at 24 hour of pre-incubation. To prove that the lack of 
induction in due to cell death an MTT should have had to been carried out. Unfortunately, this was not 
done and remains for future work. In addition, a dose response can be conducted to obtain an IC50 
value for kisspeptin in order to characterise the hormone.  
A LPS concentration of 10 ng/ml at a 4 hour stimulation time proved sufficient in terms of TNF-α 
induction. The LPS concentration of 10 ng/ml was also chosen due to the sensitivity of the ELISA. It was 
found that the response/induction was concentration dependent and not time dependent as higher 
concentrations of cytokine expression were detected due to higher concentrations of LPS which lead 
to the reading falling out of the standard curve range and therefore allowing for inaccurate 
quantification (Figure 3.6). Therefore, there would be a need for further dilutions of supernatant to 
allow for accurate cytokine quantification which was not feasible in this present study. The lower 
concentration of LPS was ultimately chosen as it was expected that kisspeptin would present with only 
minor immunomodulatory effects. It was also chosen as it was the lowest concentration that would 
provide measurable results and provide Kp-10 a better chance for inhibition. As kisspeptin showed 
better inhibition of LPS induction for TNF-α following 8 hour pre-incubation it was decided to proceed 
with a final assay design of 8 hour pre-incubation with kisspeptin followed by a 4 hour LPS stimulation 
(Figure 3.9). The pro-inflammatory cytokines TNF-α, IL-1β and IL-6 (Th1 subset) were investigated, as 
well as anti-inflammatory cytokine, IL-10 (Th2 subset). These cytokines were chosen based on their 
ability to induce and reduce inflammation respectively and based on their role in maternal immune 
tolerance formation during pregnancy.   
Previously it has been stated that the use of EDTA blood collection tubes is for specific use in gene 
expression analysis whilst NaHep blood collection tubes are optimum for protein expression analysis 
[146]. For this study we used K3 EDTA blood collection tubes as it was initially planned to compare 
gene expression to protein expression and in order to be consistent, the same blood collection tube 
was to be used. However, it was determined that EDTA tubes were not sufficient for culturing whole 
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blood as cells were unresponsive after 24 hours (Figure 3.7B). It can be suggested that the function of 
EDTA i.e. acting as a clotting and chelating agent may have an effect on protein expression following 
induction.   
This type of study was a pilot study aimed at  establishing an optimised and robust in vitro immune 
response model using whole blood which would provide the basis for extensive research into the 
immunomodulatory effects of kisspeptin within pregnant and non-pregnant women with and without 
an history of idiopathic recurrent miscarriage and/or preeclampsia. In addition, this model would allow 
for larger studies as less blood would be needed from patients to conduct experiments. The model 
presented was designed to best represent the physiological response to inflammation within the 
periphery and circulation. 
4.3.1 Kisspeptin-10 had varied effects on cytokine production 
 
The results from analysis of protein expression data indicated that LPS-induced expression of TNF-α  
(Figure 3.10A), IL-1β (Figure 3.10B) and IL-6 (Figure 3.10C) whereas there was no induction by LPS on 
IL-10 expression (Figure 3.10D). In general, Kp-10 treatment inhibited LPS induction on all cytokines 
with the exception of IL-10. In saying this the results were highly variable as kisspeptin also enhanced 
expression at some concentrations. This is with specific reference to IL-6 production whereby 
expression was slightly enhanced at concentrations of 10-8 M, 1 nM and 1 pM. The same can be seen 
for IL-1β as Kp-10 induced expression at 1 pM and 10-7 M. However, for IL-1β, induction was not 
sufficient, meaning that induction across all conditions was not great enough to achieve a measurable 
response so these results cannot be deemed reliable.  
TNF-α production (Figure 3.10A) was inhibited by kisspeptin at all concentrations, having the strongest 
inhibition from concentrations 10-10 M, 10-11 M and 1 pM. It was interesting to see that kisspeptin 
elicited stronger inhibitory effects at lower concentrations (10-10 M) as supposed to the higher 
concentrations. This could be as a results of the lower concentrations being more physiologically 
relevant [5,7,16]. An MTT assay would need to be conducted to establish the IC50/EC50 value of 
kisspeptin. This would provide the optimum concentration of kisspeptin to treat cells in order to illicit 
a response. Literature has indicated the usage of kisspeptin concentrations ranging from 4.6 pm/L to 
9.6 pmol/L [16]. In this study it was possible that the concentration of kisspeptin was too high and 
could have had the opposing effects to what has previously been seen. Positively, it was encouraging 
to observe kisspeptin’s inhibition of TNF-α using both the whole blood model and PBMC model as pro-
inflammatory cytokines, like IFN-γ and TNF-α, can either have a direct damaging effect on the placenta 
and developing fetus or indirect effect by activating cytotoxic cells, NK cells or T cells [26] Previously, 
TNF-α has been shown to induce apoptosis in human primary villous trophoblast cells whilst IFN-γ 
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enhances TNF-mediated cytotoxicity of these cells [17,35]. In addition, both the cytokines were shown 
to inhibit human trophoblast outgrowth in vitro [17,36].  As stated before, an immunological shift away 
from pro-inflammatory responses is necessary for a successful pregnancy and maternal immune 
tolerance formation.  
It was disappointing to observe no induction of IL-10 by LPS and to observe no kisspeptin-mediated 
effects on IL-10 expression. This would have provided great insight into immunomodulation by 
kisspeptin based on IL-10 having immunosuppressive capabilities [140]. As literature supports, the 
importance of IL-10 for pregnancy maintenance is essential to prevent inflammation-induced abortion, 
which was shown to occur in mice with an IL-10 knockout mutation [51]. It has been shown in mice 
that elevated concentrations of anti-inflammatory factors, such as IL-10, can prevent spontaneous 
abortions [39]. An increased production of interleukin-2 (IL-2) and IFN-γ by PBMCs along with a 
reduction in IL-10 have been associated with spontaneous miscarriage in humans [17,20]. The role of 
kisspeptin has been shown to enhance the secretion IL-10 by CD4+ T lymphocytes primed with 
transforming growth factor (TGF)-β1 which contributes to the decrease of IL-17A secretion by CD4+ T 
lymphocytes primed with IL-1β/IL-6 [16]. However, the results from this study could not validate this 
role based on the lack of IL-10 induction and Kp-10 mediated effects on IL-10 expression. It must be 
noted that in one study, it was noticed that there was much variation in results when using a whole 
blood assay, however, production of IL-10 seems to better reflect an innate pro- or anti-inflammatory 
response whereas production of TNF-α was more reflective of immediate immunological challenges 
such as LPS stimulation [143]. 
IL-6 induces the development of Th17 cells from undifferentiated T cells together with TGF-β and 
inhibits TGF-β-induced aTreg differentiation promoting inflammation during pregnancy [47]. Varied 
results were observed regarding kisspeptin mediated effects on IL-6 expression, however it was 
promising to see inhibition of IL-6 expression at lower concentrations of kisspeptin. The cytokine, IL-6, 
is multifunctional and plays a significant role in the context of this study i.e. playing a role in immune 
adaptations which are necessary for the development of immune tolerance. In short, Kp-10 inhibited 
the expression of IL-1β and IL-6 at certain concentrations. The suggestive nature of the results 
highlights the need to further optimise and repeat these experiments in future as this would have been 
a major finding if significant. As Kp-10 slightly inhibited IL-6, TNF-α and IL-1β we may suggest an 
immunomodulatory role on group 1 and group 2 type cytokines in this context. 
In future, it would be of great benefit to relate protein expression to gene expression by comparing 
protein expression analysis data to data acquired from a reverse transcription polymerase chain 
reaction (RT-PCR). This would provide a clearer indication of the immunomodulatory effects of 
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kisspeptin as well as further validation of the reproducibility of the assay. In addition, it would be 
beneficial to expand the scope in terms of cytokine profiles being investigated to those playing an 
essential role in maternal immune tolerance for example: IL-17A [47, 48] and TGF-β [47]. One would 
also need to investigate a full time course as it is known that cytokines and chemokines are expressed 
differently over a certain time duration when stimulated [136].  
Much like the earlier model test, this model does present limitations. Following further testing and 
optimisation, it may provide the necessary proof-of-concept and foundation required for further study 
into the immunomodulatory effects of kisspeptin in vitro and for an ethics application for in vivo 
studies. These experiments were to be done to establish a working in vitro infection model to be used, 
in future, to further investigate the immunomodulatory properties of Kp-10 using the blood from 
women suffering from idiopathic recurrent miscarriage (IRM) or preeclampsia outside or within 
pregnancy. One way to establish the basis for further development of the model would be to identify 
and quantify kisspeptin receptor levels via immunocytochemistry within whole blood and PBMCs as 
this could be a factor negatively affecting results due to low expression levels. In addition, one could 
expand the study and investigate primary immune cells isolated from the placenta under the same 
conditions to see the effect of Kp-10 on immune stimulation.  
 
4.4 Sodium Heparin (NaHep) blood collection tubes are more 
suitable for protein expression analysis than K3 EDTA tubes 
It has been shown that heparin enhances monocyte production of TNF following LPS-induction, whilst 
EDTA inhibits the production of LPS-induced cytokines [142,147]. The reason for this is based on the 
effect of the two anticoagulants on neutrophil-derived protein cationic antimicrobial protein of 18 kDa 
(CAP18) and heparin-binding-protein (HBP/CAP37) which inhibit and enhance LPS-induced cellular 
activation, respectively [146]. CAP18’s inhibitory effect is increased by EDTA and removed by heparin. 
In addition, the LPS-induced TNF-α response is calcium dependent and is inhibited by EDTA, confirming 
the hypothesis that EDTA is unsuitable for measuring TNF-α [144,146]. Therefore, it is important to 
consider these effects following review of the previous section and further justifies the reason for using 
NaHep blood collection tubes for testing the hypothesis. The main reason validating the use of NaHep 
tubes would be the ability to culture whole blood over an extended period of time i.e. greater than 24 
hours and still achieve measurable induction following LPS stimulation.   
The results from NaHep tubes depicted similar Kp-10 mediated effects to that seen in previous 
experiments using EDTA tubes. Since viability was low at 24 hours using EDTA tubes and literature 
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suggesting that 72 hours is optimum for kisspeptin reactivity [5], it was decided to test sodium heparin 
blood collection tubes under the same conditions. Therefore, we compared the EDTA tubes used under 
this section to that of the NaHep tubes used for the PBMC infection assay. NaHep tubes have previously 
been used for protein expression analysis [146]. Kp-10 induced IL-1β production at 24 and 48 hours 
with notable efficacious concentrations being 10-8 M. At 72 hours IL-1β expression was enhanced but 
these results were negligible based on the fact that IL-1β induction by LPS was too low for all 
treatments and controls. There was induction for IL-10 following 48 and 72 hours which was expected 
[136]. Kp-10 enhanced IL-10 production at 72 hours for 10-8 M but inhibited expression at 48 hours at 
the same concentration. This was positive to see and further justified the use of a 72 hour pre-
incubation time.  For the remaining cytokines the results were negligible in that there were not Kp-10 
mediated effects. 
 
4.5 Patient variability is a major contributor to varied results 
Patient variability was a major contributor to the negative results seen in this study. Each patient 
presented, in most cases, a completely different response to the next. One possible factor contributing 
to this could be that having patients with normal functioning immune responses, much like the 
patients in this study, may contribute to varied immune response whereas patients with compromised 
immune states may present with a more uniform or consistent response when stimulated. It is known 
that using human samples presents a large discrepancy between patients, but with a large cohort, it 
would be expected to see a trend/pattern for the majority of patients. This remains to be investigated 
as this was a low-powered study. One would need to increase the study cohort in order for the 
elucidation of reliable cytokine and chemokine expression profiles as well as the effect of Kp-10 on 
these profiles. There was a lot less inter-sample variability observed in NaHep tubes when compared 
to EDTA tubes. This observation could be attributed to the stability of cytokines within NaHep tubes, 
as previously discussed. This in conjunction with possible inconsistent sample handling could 
contribute to descrepancies observed. 
 
Conclusion 
In this study we employed an in vitro PBMC infection assay model as well as an in vitro whole blood 
infection model in order to determine the effects of kisspeptin on Mtb and LPS-induced cytokine and 
chemokine expression. Results from the PBMC infection assays showed varied yet no effect of 
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kisspeptin-10 on selected cytokine expression at 2 hours post-infection, however suggested an 
inhibitory effect of kisspeptin-10 on selected cytokine expression after 24 hours. These effects were 
not observed 6 days post-infection.  Results from the whole blood stimulation assay suggested an 
inhibitory effect of kisspeptin-10 on LPS-induced pro-inflammatory cytokines whilst generally not 
having an effect on anti-inflammatory cytokines. Overall we could only suggest an immunomodulatory 
role of kisspeptin-10 based on the observed inhibition of pro-inflammatory cytokines at the protein 
level. Again it must be stated that the data was not significant so all claims within this study are only 
indicative of potential patterns or effects, which remain to be investigated and/or seen. 
 
This study aimed to provide further insight into the role of kisspeptin in the development of maternal 
immune tolerance, based on its effect on cytokine and chemokine expression. It was a low-powered 
study aimed at establishing a model system to examine the hypothesis presented in order to justify 
further investigation and experimentation.  Understanding of key regulators and mechanisms of 
maternal immune tolerance is essential to understanding the pathophysiological mechanisms 
underlying certain pregnancy-related disorders. This is a pilot study aimed at characterising kisspeptin 
along with its role in establishing maternal immune tolerance based on its effects on several cytokines 
and chemokines. Manipulation of regulatory hormones such as kisspeptin could represent a potentially 
attractive approach in the treatment of various pregnancy-related disorders including preeclampsia 
and unexplained recurrent miscarriage, however this remains a goal for the future as the effects of 
kisspeptin and its role in such disorders as well as during pregnancy needs to be fully elucidated and 
established. 
 It is important to further investigate kisspeptin mediated regulation of cytokoines and chemokines as 
it may be possible to develop strategies to regulate the immune response toward fetal antigens via 
cytokine and chemokine manipulation through kisspeptin administration, which could induce maternal 
immune tolerance against fetal antigens throughout immune-mediated recurrent and unexplained 
spontaneous abortion. It is imperative to establish a foundation for further investigations as one 
cannot get too excited about potential applcations until the underlying mechanisms have been 
elucidated and therefore better understood. If kisspeptin does indeed play a role in immune tolerance 
formation during pregnancy, then we can move forward to investigating therapeutic 
applications.Further studies would need to be done to elucidate the role played by kisspeptin in 
maternal immune tolerance formation.  
Despite the non-conclusive/-significant nature of the results presented in this study, hopefully this 
study has outlined the potential for further research into the potential immunomodulatory roles of 
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Appendix A  Reagent Recipes 
10X Ammonium, Calcium and Potassium  
(ACK) lysis buffer 82.9 g NH4Cl; 10 g KHCO3; 0.372 g EDTA – fill up to 
1 000 ml with dH2O, pH 7.2  
 
 




7H9 media     2.4 g Agar; 450 ml dH2O and 1 ml Glycerol 
 
 
7H11 media     21 g Agar; 900 ml dH2O and 5 ml Glycerol 
 
 
MTT Reagent  5 mg/ml MTT reagent, Cat no. M2128 (Sigma 
Aldrich) in 1X PBS, pH 7.4 
 
 
0.05% Sodium dodecyl sulphate (SDS)  Prepare 10% master stock – 50 g SDS in 500 ml dH2O 
then make 1:200 dilution by adding 1 ml of 10% SDS 
to 199 ml of dH2O 
 
 
ELISA coating buffer 0.1 M Sodium Carbonate, pH 9.5; 7.13 g NaHCO3; 




ELISA wash buffer    1X PBS with 0.05% Tween-20  
 
 
ELISA assay diluent    1X PBS with 10% fetal bovine serum (FBS), pH 7.0 
  
  








Appendix B Luminex assay protocol 
Summarised version of protocol taken from – MILLIPLEX® MAP HUMAN CYTOKINE/CHEMOKINE 
MAGNETIC BEAD PANEL KIT 96 Well Plate Assay Cat. # HCYTOMAG-60K. Instruction Manual 
 
NOTE: All reagents provided in kit 
 
Allow all reagents to warm to room temperature (20-25C) before use in the assay. 
 
1. Add 200 µL of Wash Buffer into each well of the plate. Seal and mix on a plate shaker for 10 
minutes at room temperature (20-25C).  
 
2. Decant Wash Buffer and remove the residual amount from all wells by inverting the plate and 
tapping it smartly onto absorbent towels several times. 
 
3. Add 25 µL of each Standard or Control into the appropriate wells. Assay Buffer should be used 
for 0 pg/mL standard (Background).  
 
4. Add 25 µL of Assay Buffer to the sample wells.  
 
5. Add 25 µL of appropriate matrix solution to the background, standards, and control wells. 
When assaying serum or plasma, use the Serum Matrix provided in the kit. When assaying 
tissue culture or other supernatant, use proper control culture medium as the matrix solution.  
 
6. Add 25 µL of serum/plasma Sample (1:100 dilution for RANTES, PDGF-AA, and PDGF-BB, Neat 
for all other 38 cytokines) or 25 μl cell culture sample into the appropriate wells.  
 
7. Vortex Mixing Bottle and add 25 μL of the Mixed or Premixed Beads to each well. (Note: During 
addition of Beads, shake bead bottle intermittently to avoid settling.)  
 
8. Seal the plate with a plate sealer. Wrap the plate with foil and incubate with agitation on a 
plate shaker overnight at 4C or 2 hours at room temperature (20- 25C). An overnight 
incubation (16-18 hr) may improve assay sensitivity for some analytes.  
 
9. Gently remove well contents and wash plate 2 times following instructions listed in the PLATE 
WASHING section (included in manual).  
 
10. Add 25 µL of Detection Antibodies into each well. (Note: Allow the Detection Antibodies to 
warm to room temperature prior to addition.)  
 
11. Seal, cover with foil and incubate with agitation on a plate shaker for 1 hour at room 
temperature (20- 25C). DO NOT ASPIRATE AFTER INCUBATION.  
 





13. Seal, cover with foil and incubate with agitation on a plate shaker for 30 minutes at room 
temperature (20- 25C).  
 
14. Gently remove well contents and wash plate 2 times following instructions listed in the PLATE 
WASHING section.  
 
15. Add 150 µL of Sheath Fluid (or Drive Fluid if using MAGPIX®) to all wells. Resuspend the beads 
on a plate shaker for 5 minutes.  
 
16. Run plate on Luminex 200™, HTS, FLEXMAP 3DTM or MAGPIX® with xPONENT software.  
 
17. Save and analyze the Median Fluorescent Intensity (MFI) data using a 5-parameter logistic or 
spline curve-fitting method for calculating cytokine/chemokines concentrations in samples. 
(Note: For diluted samples, multiply the calculated concentration by the dilution factor.) 
 
All reagent prep and general instructions can be found in manual. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
